Page last updated: 2024-11-04

glutamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Glutamine: A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

L-glutamine : An optically active form of glutamine having L-configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

glutamine : An alpha-amino acid that consists of butyric acid bearing an amino substituent at position 2 and a carbamoyl substituent at position 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5961
CHEMBL ID930
CHEBI ID28300
CHEBI ID18050
SCHEMBL ID7453
SCHEMBL ID19240116
SCHEMBL ID23124227
MeSH IDM0009383

Synonyms (218)

Synonym
AB00173347-03
gtpl723
glutamine, l-
(2s)-2,5-diamino-5-oxopentanoic acid
l-glutamin
glutamic acid gamma-amide
(s)-2,5-diamino-5-oxopentanoic acid
CHEBI:28300 ,
l-glutaminsaeure-5-amid
l-(+)-glutamine
glutaminsaeure-5-amid
hgln
l-glutamic acid gamma-amide
(2s)-2-amino-4-carbamoylbutanoic acid
CHEBI:18050 ,
l-glutamid
nsc-27421
l-2-aminoglutaramidic acid
l-glutamic acid .gamma.-amide
miglu-p
l-glutamide
glutamic acid amide
glutamine,l-
levoglutamide
stimulina
cebrogen
DIVK1C_006476
KBIO1_001420
SDCCGMLS-0066691.P001
EU-0100549
l-glutamine, reagentplus(r), >=99% (hplc)
l-glutamine (jp17)
glutamine (usp)
nutrestore (tn)
D00015
endari (tn)
SPECTRUM4_001709
SPECTRUM_000131
einecs 200-292-1
nsc 27421
l-glutamine [jan]
levoglutamida [inn-spanish]
levoglutamidum [inn-latin]
brn 1723797
SPECTRUM5_000418
LOPAC0_000549
glumin (amino acid)
2-aminoglutaramic acid, l-
glavamin
fema no. 3684
levoglutamid
levoglutamina
ai3-24392
l-glutamic acid 5-amide
2,5-diamino-5-oxopentanoic acid, (s)-
glutamine (van)
pentanoic acid, 2,5-diamino-5-oxo-, (s)-
l-2-aminoglutaramic acid
GLN ,
C00064
l-glutamine
56-85-9
l-gln
2-aminoglutaramic acid
glumin
glutamic acid 5-amide
glutamine
l-glutamine, meets usp testing specifications, cell culture tested, 99.0-101.0%, from non-animal source
l-glutamine, gamma-irradiated, bioxtra, suitable for cell culture
DB00130
1WDN
BSPBIO_003092
NCGC00093936-02
KBIO2_003159
KBIO3_002312
KBIO2_005727
KBIOGR_002038
KBIOSS_000591
KBIO2_000591
SPECPLUS_000380
SPECTRUM2_001377
SPECTRUM3_001416
SPBIO_001334
SPECTRUM1500987
NCGC00093936-03
NCGC00093936-01
NCGC00093936-04
l-glutamine, bioultra, >=99.5% (nt)
s(+)-glutamic acid 5-amide
7FBA778C-D6B8-495C-BFE7-1CB8EC4ABEAB
G 3126
NCGC00093936-05
CHEMBL930 ,
glutamine [usan]
BMSE000038
levoglutamide [dcf:inn]
G0063
h-gln-oh
A831906
HMS3261N19
HMS3264C03
d(-)-glutamine
glutamine [usan:usp:inn]
l-glutamine [jan]
unii-0rh81l854j
levoglutamida
ccris 9428
hsdb 8165
levoglutamidum
saforis
nutrestore
4-04-00-03038 (beilstein handbook reference)
0rh81l854j ,
pharmakon1600-01300018
nsc-760081
nsc760081
nsc-759628
nsc759628
pharmakon1600-01500987
BMSE001014
CCG-38853
gamma-glutamine
BP-13284
LP00549
glutamine [inn]
glutamine [vandf]
l-glutamine [fhfi]
glutamine [mart.]
glutamine [inci]
glutamine [usp-rs]
glutamine [usp monograph]
l-glutamine [orange book]
l-glutamine [vandf]
endari
l-glutamine [fcc]
glutamine [orange book]
glutamine [mi]
levoglutamide [who-dd]
S1749
AKOS015854078
BRD-K83896451-001-01-8
gtpl4634
[14c]glutamine
[3h]-glutamine
[3h]glutamine
[14c]-glutamine
gtpl4633
CS-1947
HY-N0390
bdbm18121
l-[3,4-3h(n)]glutamine
AM81759
SCHEMBL7453
tox21_500549
NCGC00261234-01
h-gln
(s)-2-amino-4-carbamoyl-butyric acid
(s)-glutamine
3h-l-glutamine
glutamine-s
glutamine (l)
l-alanyl-l-glutamide
Q-100459
n-(2)-l-alanyl-l-glutamine
AB00173347_04
mfcd00008044
DTXSID1023100 ,
l-glutamine, cell culture reagent (h-l-gln-oh)
J-521645
F0001-1471
s(+)glutamine
l-glutamine, certified reference material, tracecert(r)
M02960
glutamine, united states pharmacopeia (usp) reference standard
l-glutamine, saj special grade, >=99.0%
l-glutamine, pharmaceutical secondary standard; certified reference material
l-glutamine, 98.5%
l-glutamine, vetec(tm) reagent grade, >=99%
glutamine (l-glutamine)
glutamina
SBI-0050532.P003
(s)-2,5-diamino-5-oxopentanoate
(2s)-2-amino-4-carbamoylbutanoate
l glutamine
SCHEMBL19240116
l-glutamine,(s)
AS-11765
Q181619
s(+)-glutamine
SDCCGSBI-0050532.P005
NCGC00093936-15
D70833
EN300-52640
SCHEMBL23124227
STARBLD0006818
A937790
l-glutamine, cell culture grade
(s)-2,5-diamino-5-oxopentanoic acid, l-glutamic acid 5-amide
sympt-x g.i.
glutasolve
glutamine (usp-rs)
glutapak-10
memoril
q. levoglutamide
glutaven
glutamine (mart.)
gebrogen
glutamic acid-5-amide
resource glutasolve
(s)-2-aminopentane-dioic acid 5-amide
1-2-aminoglutaramidic acid
l-glutaminsaure-5-amid
dtxcid503100
sympt-x
glutamine (usp monograph)
glutaminum
glutacerebro
Z756440074

Research Excerpts

Toxicity

Glutamine was well tolerated and no adverse events occurred. We propose a mechanism by which glutamine executes its toxic effects in astrocytes, the "Trojan horse" hypothesis.

ExcerptReferenceRelevance
" No evidence of clinical toxicity or generation of toxic metabolites (ammonia and glutamate) was observed."( Safety and metabolic effects of L-glutamine administration in humans.
Benfell, K; Brown, E; Ferrari-Baliviera, E; Lowe, DK; Smith, RJ; Wilmore, DW; Young, LS; Ziegler, TR,
)
0.13
" Ammonia and glutamate, potentially toxic metabolites of glutamine, did not change significantly with glutamine enrichment."( Safety of glutamine-enriched parenteral nutrient solutions in humans.
Benfell, K; Jacobs, DO; Lowe, DK; Murawski, B; Smith, RJ; Wilmore, DW; Ziegler, TR, 1990
)
0.28
" The antioxidants glutathione, vitamin E and vitamin C reversed toxicity and antimitochondrial activity to a large extent implying that toxic free radical metabolites of the drug are of significance in cellular activity of MGBG."( Effect of antioxidants on the mitochondrial activity and toxicity of the cancer drug methylglyoxal bis (guanylhydrazone) in yeast and mammalian cells.
Cheng, LL; Collier, DC; Wilkie, D, 1990
)
0.28
" We have investigated the toxic effects of these compounds on pancreatic tissues from Wistar rats and Syrian hamsters."( Cellular toxicity of pancreatic carcinogens.
Archer, MC; Chan, AM; Zucker, PF, 1986
)
0.27
" The intraperitoneal administration of toxic doses of l-2,4-diaminobutyric acid to rats resulted in hyperirritability, tremors and convulsions in 12-20hr."( The 'neurotoxicity' of L-2,4-diaminobutyric acid.
Chen, CH; Koeppe, RE; Meghal, SK; O'Neal, RM; Reynolds, CS, 1968
)
0.25
"The mushroom metabolite gamma-L-glutaminyl-3,4-dihydroxybenzene (GDHB) was found to have an LD50 of 100 to 200 mg/kg in neonatal C57Bl/6J mice."( The role of gamma-glutamyl transpeptidase in the nephrotoxicity of an Agaricus bisporus metabolite.
Boekelheide, K; Graham, DG; Mize, PD; Vogel, FS, 1980
)
0.26
" In an initial non-blinded study, L-glutamic acid (15 mM) exerted a significant toxic effect on HD fibroblasts, decreasing viability by approximately 60% after 48 h exposure."( Effects of L-glutamate on viabilities of cultured diploid skin fibroblasts and lymphocytes. Increased toxicity not observed in Huntington's disease.
Bird, TD; Casper, JB; Stahl, WL; Ward, CB,
)
0.13
"Supplementation of glutamine dipeptide was safe but had no significant positive clinical effect."( Parenteral glutamine dipeptide supplementation does not ameliorate chemotherapy-induced toxicity.
Fürst, P; Sauerwein, HP; Timmer, JG; van der Lelie, H; van Zaanen, HC, 1994
)
0.29
" Thus, the administration of even high doses of GLY-GLN is feasible and safe in patients with polytrauma and is not associated with any relevant renal substrate loss."( Safety and efficacy of increasing dosages of glycyl-glutamine for total parenteral nutrition in polytrauma patients.
Fridrich, P; Germann, P; Götzinger, P; Karner, J; Mauritz, W; Mittlböck, M; Roth, E; Weingartmann, G, 1996
)
0.29
" In addition, we find the aberrant metabolism of expanded repeat AR to be coupled to cellular toxicity, indicating a likely molecular basis for the toxic gain of AR function that produces neuronal degeneration in SBMA."( Cleavage, aggregation and toxicity of the expanded androgen receptor in spinal and bulbar muscular atrophy.
Bailey, CK; Fischbeck, KH; Kobayashi, Y; Merry, DE; Taye, AA, 1998
)
0.3
"These studies suggest that GLN supplementation is safe in its administration to the tumor-bearing host receiving MTX."( Effect of glutamine on methotrexate efficacy and toxicity.
Cao, Y; Hutchins, LF; Klimberg, VS; Rubio, IT; Westbrook, KC, 1998
)
0.3
" Commercial gamma-glutamyl-p-nitroanilide (GGPNA) was not toxic or mutagenic."( Gamma-glutamyl transpeptidase-dependent mutagenicity and cytotoxicity of gamma-glutamyl derivatives: a model for biochemical targeting of chemotherapeutic agents.
Keren, R; Stark, AA, 1998
)
0.3
" These observations indicate that the astrocyte population is a potential target for Al toxic action that could mediate the pathogenesis of this metal."( Effects of aluminum exposure on glutamate metabolism: a possible explanation for its toxicity.
Guillard, O; Struys-Ponsar, C; van den Bosch de Aguilar, P, 2000
)
0.31
" This article analyzes the literature on the safety of glutamine and also examines the available information on high intakes of total protein and other amino acids, so that additional indicators of potentially adverse effects can be suggested."( Assessment of the safety of glutamine and other amino acids.
Garlick, PJ, 2001
)
0.31
"To develop the safe absorption-enhancing formulation attenuating the local toxicity caused by an absorption enhancer, sodium laurate (C12), the effects of amino acids on the local toxicity by C12 were examined in rats."( Amino acids protect epithelial cells from local toxicity by absorption enhancer, sodium laurate.
Endo, Y; Higaki, K; Kimura, T; Ogawara, K; Sone, M; Yata, T, 2001
)
0.31
"Several studies have suggested that dietary supplementation with antioxidants can influence the response to chemotherapy as well as the development of adverse side effects that result from treatment with antineoplastic agents."( The effects of oral glutamine on cisplatin-induced genotoxicity in Wistar rat bone marrow cells.
Antunes, LM; Bianchi, ML; Francescato, HD; Mora, Lde O, 2002
)
0.31
" "In vivo" transient expression assays showed that deletion of the last 80 amino acids of the carboxyl terminus produces a form of the protein that is highly toxic to larvae."( "In vivo" toxicity of a truncated version of the Drosophila Rst-IrreC protein is dependent on the presence of a glutamine-rich region in its intracellular domain.
Costa, MS; Machado, RC; Pereira, RN; Ramos, RG, 2002
)
0.31
" We reviewed the available data on the use of glutamine to decrease the incidence and severity of adverse effects due to chemotherapy and/or radiation in cancer patients."( Prevention of chemotherapy and radiation toxicity with glutamine.
Corey, B; Savarese, DM; Savy, G; Vahdat, L; Wischmeyer, PE, 2003
)
0.32
" Three double-blind studies examined the safety of the combination of HMB, arginine and glutamine on blood chemistries, hematology, emotional profile, and adverse events."( Supplementation with a combination of beta-hydroxy-beta-methylbutyrate (HMB), arginine, and glutamine is safe and could improve hematological parameters.
Abumrad, NN; Barber, AE; Clark, RH; D'Olimpio, J; Eubanks May, P; Nissen, S; Panton, L; Rathmacher, JA,
)
0.13
"Across the 3 studies, HMB, arginine, and glutamine supplementation was not associated with any adverse indicators of health."( Supplementation with a combination of beta-hydroxy-beta-methylbutyrate (HMB), arginine, and glutamine is safe and could improve hematological parameters.
Abumrad, NN; Barber, AE; Clark, RH; D'Olimpio, J; Eubanks May, P; Nissen, S; Panton, L; Rathmacher, JA,
)
0.13
"Gastrointestinal tolerance of the supplement was excellent: no adverse events related to the product were documented."( Early enteral gut feeding with conditionally indispensable pharmaconutrients is metabolically safe and is well tolerated in postoperative cancer patients--a pilot study.
Alteheld, B; Deska, T; Haaker, R; Hummel, T; Senkal, M; Stehle, P; Steinfort, C; Zumtobel, V, 2004
)
0.32
"Early postoperative gut feeding with the newly developed enteral supplement shows no adverse effects, is well tolerated in cancer patients and provides a novel method to deliver conditionally indispensable pharmaconutrients."( Early enteral gut feeding with conditionally indispensable pharmaconutrients is metabolically safe and is well tolerated in postoperative cancer patients--a pilot study.
Alteheld, B; Deska, T; Haaker, R; Hummel, T; Senkal, M; Stehle, P; Steinfort, C; Zumtobel, V, 2004
)
0.32
"Oral administration of glutamine could be helpful to increase plasma concentration of glutamine and to ameliorate obviously the intestinal mucosal injury, to promote systemic protein synthesis and to inhibit protein catabolism and to upgrade systemic immune function with little side effect in patients with severe injury."( [Analysis of the therapeutic effect and the safety of glutamine granules per os in patients with severe burns and trauma].
He, GZ; Huang, XK; Peng, X; Quan, ZF; Wang, SL; Xie, WG; You, ZY; Zhang, CQ, 2004
)
0.32
"Study feed is well tolerated and metabolically safe representing a valuable tool for targeted pharmaconutrient supply."( Safety and intestinal tolerance of high-dose enteral antioxidants and glutamine peptides after upper gastrointestinal surgery.
Alteheld, B; Berger, MM; Cayeux, MC; Chioléro, RL; Schroeder, J; Stehle, P, 2005
)
0.33
" Simultaneously, decreased expression of GLT-1 mRNA and protein was observed, indicating that of the two glial transporters, GLT-1 is more susceptible to the toxic Pb effect."( The role of astroglia in Pb-exposed adult rat brain with respect to glutamate toxicity.
Chalimoniuk, M; Struzyńska, L; Sulkowski, G, 2005
)
0.33
" As a microbial TG is included in many food technological processes, its safe use should be checked."( Transglutaminases: a meeting point for wheat allergy, celiac disease, and food safety.
Malandain, H, 2005
)
0.33
"The toxic effect of ammonia on rCHO-GS cell decreased obviously due to the transfection of GS system in serum-free culture."( [Metabolism of recombinant CHO-GS cell reducing of toxic effect of ammonia].
Sun, XM; Yi, XP; Zhang, F; Zhang, YX, 2006
)
0.33
" We also propose a mechanism by which glutamine executes its toxic effects in astrocytes, the "Trojan horse" hypothesis."( Glutamine: a Trojan horse in ammonia neurotoxicity.
Albrecht, J; Norenberg, MD, 2006
)
0.33
" Inhibiting mitochondrial glutamine hydrolysis in astrocytes mitigates many of the toxic effects of ammonia, suggesting the involvement of mitochondrial glutamine metabolism in the mechanism of ammonia neurotoxicity."( Inhibition of glutamine transport into mitochondria protects astrocytes from ammonia toxicity.
Jayakumar, AR; Norenberg, MD; Pichili, VB; Rao, KV, 2007
)
0.34
"Glutamine was well tolerated and no adverse events occurred."( Enteral glutamine during active shock resuscitation is safe and enhances tolerance of enteral feeding.
Ahn, C; Kozar, R; McKinley, B; McQuiggan, M; Moore, F; Sailors, RM,
)
0.13
"Enteral glutamine administered during active shock resuscitation and through the early postinjury period is safe and enhances gastrointestinal tolerance."( Enteral glutamine during active shock resuscitation is safe and enhances tolerance of enteral feeding.
Ahn, C; Kozar, R; McKinley, B; McQuiggan, M; Moore, F; Sailors, RM,
)
0.13
" Comparing with the EC(50) values of cadmium chloride and mercury chloride, [bmim]BF(4) is not very toxic, but it may have a long-term toxic effect on mammalian cells."( Conductive polymer as a controlled microenvironment for the potentiometric high-throughput evaluation of ionic liquid cell toxicity.
Qiu, W; Zeng, X, 2008
)
0.35
" In the absence of controlled trials, it is currently not possible to estimate a safe upper limit for either of these 2 amino acids."( Glutamine metabolism and function in relation to proline synthesis and the safety of glutamine and proline supplementation.
Watford, M, 2008
)
0.35
"Forty-four patients with gastric or colorectal cancer developing WHO side-effect grading system of grade 2 or higher were randomized to either control group (n = 22) or Gln group (n = 22) during next cycle of chemotherapy."( Clinical trial: prophylactic intravenous alanyl-glutamine reduces the severity of gastrointestinal toxicity induced by chemotherapy--a randomized crossover study.
Li, J; Li, Y; Liu, F; Ni, X; Ping, X; Yu, B, 2009
)
0.35
" The changes of main Chinese medicine clinical symptoms and signs, including stomachache, diarrhea, mucous or bloody stool before and after treatment, and their adverse reactions were observed after the two-week treatment."( Safety and efficacy of Qingre Buyi Decoction in the treatment of acute radiation proctitis: a prospective, randomized and controlled trial.
Liu, JH; Tu, XH; Wang, L; Wang, Y; Zhang, ZZ; Zou, ZD, 2009
)
0.35
" In addition, no severe adverse event was found in both groups."( Safety and efficacy of Qingre Buyi Decoction in the treatment of acute radiation proctitis: a prospective, randomized and controlled trial.
Liu, JH; Tu, XH; Wang, L; Wang, Y; Zhang, ZZ; Zou, ZD, 2009
)
0.35
" The combination of conventional treatment with Chinese herbal medicine QBD is effective and safe for ARP."( Safety and efficacy of Qingre Buyi Decoction in the treatment of acute radiation proctitis: a prospective, randomized and controlled trial.
Liu, JH; Tu, XH; Wang, L; Wang, Y; Zhang, ZZ; Zou, ZD, 2009
)
0.35
" Neither adverse clinical effects nor clinically significant laboratory changes were noted during L-Gln supplementation."( The safety of oral use of L-glutamine in middle-aged and elderly individuals.
Coelho, ZC; de Vasconcelos, PR; de Vasconcelos, RC; Fechine, FV; Galera, SC; Teixeira, MJ, 2010
)
0.36
" Adverse events were comparable for the two drugs; 2 subjects experienced hyperammonemic events on NaPBA while none occurred on GPB."( Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control.
Beliveau, M; Berry, SA; Diaz, GA; Dickinson, K; Gargosky, S; Lee, B; Marier, JF; Martinez, A; Mauney, J; Mian, A; Mokhtarani, M; Rhead, W; Scharschmidt, BF; Shchelochkov, O, 2010
)
0.36
"In epilepsy, traumatic brain injury, and ischemic stroke, toxic levels of zinc released from neurons contribute to the brain damage associated with these disorders."( Histidine, cystine, glutamine, and threonine collectively protect astrocytes from the toxicity of zinc.
Bishop, GM; Campbell, MS; Ralph, DM; Robinson, SR, 2010
)
0.36
"Nephrotoxicity is one of the adverse side effects of cyclophosphamide (CP) chemotherapy."( The effects of oral glutamine on cyclophosphamide-induced nephrotoxicity in rats.
Abraham, P; Isaac, B, 2011
)
0.37
"The abbreviation of preoperative fasting to 2 h with carbohydrate and L-glutamine is safe and does not increase the RGV during induction of anesthesia."( Safety of oral glutamine in the abbreviation of preoperative fasting: a double-blind, controlled, randomized clinical trial.
Aguilar-Nascimento, JE; Borges Dock-Nascimento, D; Bragagnolo, R; Caporossi, C; Caporossi, FS; Linetzky Waitzberg, D; Sepulveda Magalhães Faria, M,
)
0.13
"To review recent articles, published between October 2009 and September 2011, that examined the adverse metabolic consequences of perioperative fasting and interventions that may be utilized to minimize these effects."( Metabolic conditioning to attenuate the adverse effects of perioperative fasting and improve patient outcomes.
Awad, S; Lobo, DN, 2012
)
0.38
"Numerous perioperative interventions are available, which if utilized should help attenuate the adverse effects of perioperative fasting and lead to improved patient outcomes."( Metabolic conditioning to attenuate the adverse effects of perioperative fasting and improve patient outcomes.
Awad, S; Lobo, DN, 2012
)
0.38
"Glutamate is the main excitatory neurotransmitter in the retina, but it is toxic when present in excessive amounts."( Effect of Angeli's salt on the glutamate/glutamine cycle activity and on glutamate excitotoxicity in the hamster retina.
Chianelli, MS; Dorfman, D; Knott, ME; Sáenz, DA, 2012
)
0.38
"Expression of huntingtin fragments with 103 glutamines (HttQ103) is toxic in yeast containing either the [PIN(+)] prion, which is the amyloid form of Rnq1, or [PSI(+)] prion, which is the amyloid form of Sup35."( Sequestration of Sup35 by aggregates of huntingtin fragments causes toxicity of [PSI+] yeast.
Eisenberg, E; Greene, LE; Masison, D; Moomau, C; Park, YN; Todor, H; Zhao, X, 2012
)
0.38
" These results indicate that dietary supplementation with up to 4 % MSG is safe and improves growth performance in postweaning pigs."( Dietary supplementation with monosodium glutamate is safe and improves growth performance in postweaning pigs.
Dahanayaka, S; Eide, SJ; Ficken, MD; Fielder, SE; Knabe, DA; Lovering, SL; Rezaei, R; Tekwe, CD; Wu, G, 2013
)
0.39
" Despite its essentiality, at excessive levels Mn is toxic to the central nervous system (CNS)."( Manganese toxicity in the central nervous system: the glutamine/glutamate-γ-aminobutyric acid cycle.
Aschner, M; Sidoryk-Wegrzynowicz, M, 2013
)
0.39
"The National Institutes of Health-appointed CRISIS Data and Safety Monitoring Board was charged with monitoring sample size adequacy and feasibility, safety with respect to adverse events and 28-day mortality, and efficacy with respect to the primary nosocomial infection/sepsis outcome."( The role of the Data and Safety Monitoring Board in a clinical trial: the CRISIS study.
Anand, KJ; Berger, J; Casper, TC; Dean, JM; Harrison, R; Holubkov, R; Meert, KL; Newth, CJ; Nicholson, C; Willson, DF; Zimmerman, J, 2013
)
0.39
" OP is safe in healthy subjects and in stable patients with cirrhosis, but there are no data in decompensated cirrhosis."( Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open-label, dose-escalating, single-cohort study.
Arranz, JA; Blanco, A; Córdoba, J; Fuentes, I; Riudor, E; Simón-Talero, M; Soriano, G; Suñé, P; Torrens, M; Ventura-Cots, M,
)
0.13
"No severe adverse events were observed."( Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open-label, dose-escalating, single-cohort study.
Arranz, JA; Blanco, A; Córdoba, J; Fuentes, I; Riudor, E; Simón-Talero, M; Soriano, G; Suñé, P; Torrens, M; Ventura-Cots, M,
)
0.13
"OP is a safe and well-tolerated drug in decompensated cirrhotics that may decrease plasma ammonia by inducing its appearance as phenylacetylglutamine in urine."( Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open-label, dose-escalating, single-cohort study.
Arranz, JA; Blanco, A; Córdoba, J; Fuentes, I; Riudor, E; Simón-Talero, M; Soriano, G; Suñé, P; Torrens, M; Ventura-Cots, M,
)
0.13
" PAA plasma levels ≥ 500 μg/dL have been reported to be associated with reversible neurological adverse events (AEs) in cancer patients receiving PAA intravenously."( Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Bartley, J; Berquist, W; Berry, SA; Brown, RS; Coakley, D; Diaz, GA; Dickinson, K; Feigenbaum, A; Gallagher, R; Ghabril, M; Harding, C; Lee, B; Lemons, C; Lichter-Konecki, U; Longo, N; Mantry, P; McCandless, SE; Milikien, DA; Mokhtarani, M; Moors, T; Nagamani, SC; Norris, C; Rhead, W; Rockey, DC; Scharschmidt, BF; Schulze, A; Smith, W; Vierling, JM, 2013
)
0.39
" These strategies can be categorized into (1) enhancement of ammonia excretion and reduction of ammonia entry, (2) conversion of ammonia to a less toxic product for accumulation and subsequent excretion, (3) reduction of ammonia production and avoidance of ammonia accumulation and (4) tolerance of ammonia at cellular and tissue levels."( Excretory nitrogen metabolism and defence against ammonia toxicity in air-breathing fishes.
Chew, SF; Ip, YK, 2014
)
0.4
" GLN consumption in visceral tissues frequently exceeds its release from muscle resulting in GLN deficiency that may exert adverse effects on the course of the disease."( Glutamine deficiency in extracellular fluid exerts adverse effects on protein and amino acid metabolism in skeletal muscle of healthy, laparotomized, and septic rats.
Holecek, M; Sispera, L, 2014
)
0.4
" There were no adverse events associated with supplementation and horses in both groups showed normal weight gain, clinical signs, hematology and chemistry."( Seventy day safety assessment of an orally ingested, l-glutamine-containing oat and yeast supplement for horses.
Anderson, SC; Lindinger, MI, 2014
)
0.4
" Despite its essentiality, at excessive levels Mn is toxic to the central nervous system."( Impairment of glutamine/glutamate-γ-aminobutyric acid cycle in manganese toxicity in the central nervous system.
Sidoryk-Wegrzynowicz, M, 2014
)
0.4
" These results indicate that dietary supplementation with L-arginine (up to 630 mg/kg body weight/day) is safe in pigs for at least 91 days."( Safety of long-term dietary supplementation with L-arginine in pigs.
Hu, S; Li, X; McNeal, CJ; Meininger, CJ; Rezaei, R; Wu, G, 2015
)
0.42
" Other clinical outcomes and adverse events were similar."( Efficacy and Safety of Glutamine-supplemented Parenteral Nutrition in Surgical ICU Patients: An American Multicenter Randomized Controlled Trial.
Blumberg, HM; Collier, BR; Cotsonis, GA; Dave, N; Easley, KA; Evans, ME; Galloway, JR; Griffith, DP; Hao, L; Hebbar, G; Jensen, GL; Jones, DP; Kudsk, KA; Leong, T; Manatunga, AK; Martin, GS; May, AK; Rosenberg, ES; Sax, HC; Wischmeyer, PE; Ziegler, TR, 2016
)
0.43
" Glutamine uptake is increased in activated macrophages leading us to hypothesize that in the context of excess lipids glutamine metabolism could overwhelm the mitochondria and promote the accumulation of toxic metabolites."( Glutamine Modulates Macrophage Lipotoxicity.
He, L; Schilling, JD; Weber, KJ, 2016
)
0.43
" Safety endpoints included adverse events, hyperammonemic crises (HACs), and growth and development."( Safety and efficacy of glycerol phenylbutyrate for management of urea cycle disorders in patients aged 2months to 2years.
Berry, SA; Diaz, GA; Ficicioglu, C; Harding, CO; Lichter-Konecki, U; Longo, N; McCandless, SE; Robinson, B; Smith, WE; Vockley, J; Zori, R, 2017
)
0.46
" Adverse events occurring in at least 10% of patients while on GPB were neutropenia, vomiting, diarrhea, pyrexia, hypophagia, cough, nasal congestion, rhinorrhea, rash/papule."( Safety and efficacy of glycerol phenylbutyrate for management of urea cycle disorders in patients aged 2months to 2years.
Berry, SA; Diaz, GA; Ficicioglu, C; Harding, CO; Lichter-Konecki, U; Longo, N; McCandless, SE; Robinson, B; Smith, WE; Vockley, J; Zori, R, 2017
)
0.46
"GPB was safe and effective in UCD patients aged 2months to 2years."( Safety and efficacy of glycerol phenylbutyrate for management of urea cycle disorders in patients aged 2months to 2years.
Berry, SA; Diaz, GA; Ficicioglu, C; Harding, CO; Lichter-Konecki, U; Longo, N; McCandless, SE; Robinson, B; Smith, WE; Vockley, J; Zori, R, 2017
)
0.46
" Of the reported serious adverse events (AEs), which included 11 deaths, none was attributable to study medication."( Safety, tolerability, and pharmacokinetics of l-ornithine phenylacetate in patients with acute liver injury/failure and hyperammonemia.
Bukofzer, S; Clasen, K; Durkalski, V; Fontana, RJ; Ganger, D; Gottfried, M; Hameed, B; Hanje, AJ; Koch, D; Lee, WM; Little, L; Ravis, WR; Sherker, A; Stravitz, RT; Subramanian, RM, 2018
)
0.48
" Our discovery of canagliflozin-mediated simultaneous inhibition of GDH and ETC complex I in renal cells at clinically relevant concentrations, and their particular susceptibility to necrotic cell death during proliferation, provides a mechanistic rationale for the adverse effects observed especially in patients with preexisting chronic kidney disease or previous kidney injury characterized by sustained regenerative tubular epithelial cell proliferation."( Canagliflozin mediated dual inhibition of mitochondrial glutamate dehydrogenase and complex I: an off-target adverse effect.
Beneke, S; Delp, J; Dietrich, DR; Gutbier, S; Leist, M; Schlichenmaier, N; Secker, PF, 2018
)
0.48
"One of the major concerns about taking amino acid supplements is their potential adverse effects on the kidney as a major organ involved in the metabolism and excretion of exogenous substances."( The Renal Safety of L-Carnitine, L-Arginine, and Glutamine in Athletes and Bodybuilders.
Davani-Davari, D; Karimzadeh, I; Khalili, H; Sagheb, MM, 2019
)
0.51
"Cadmium (Cd), a naturally occurring heavy metal, is toxic to animals and plants."( Glutamate alleviates cadmium toxicity in rice via suppressing cadmium uptake and translocation.
Huang, J; Jiang, J; Jiang, M; Li, M; Li, S; Shu, Q; Song, S; Tan, Y, 2020
)
0.56
" To determine which structural motifs might be less toxic than others, we assessed five variants of α-gliadin immunodominant CD-toxic peptides synthesised as 16mers in CD T cell stimulation assays with gluten-sensitive T cell lines generated from duodenal biopsies from CD-affected individuals."( Natural variants of α-gliadin peptides within wheat proteins with reduced toxicity in coeliac disease.
Ciclitira, PJ; Côrte-Real, B; Japelj, N; Messing, J; Suligoj, T; Zhang, W, 2020
)
0.56
"This study aimed to investigate the correlation of L-asparaginase (L-asp) activity, anti-L-asp antibody, asparagine and glutamine levels with the risks of adverse events (AEs), especially anaphylaxis, in pediatric acute lymphoblastic leukemia (ALL) patients who underwent polyethylene glycol-conjugated L-asp (PEG-asp)-contained treatment."( Correlation of L-asp Activity, Anti-L-asp Antibody, Asn and Gln With Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL Patients.
Chen, C; Chen, J; Huang, S; Shen, S; Wu, J; Zhang, S,
)
0.13
" Phenylacetic acid (PAA) plasma exposure has been reported to correlate with neurologic adverse events in patients with cancer but not in patients with urea cycle disorders or hepatic encephalopathy."( Exposures of Phenylacetic Acid and Phenylacetylglutamine Across Different Subpopulations and Correlation with Adverse Events.
Mak, C; Poola, N; Tseng, J; Vilchez, RA; Wang, X, 2021
)
0.62
"This analysis summarized the pharmacokinetics and safety of ornithine phenylacetate to support the dosing strategy and to assist with the monitoring and management of neurologic adverse events in a global clinical development program."( Exposures of Phenylacetic Acid and Phenylacetylglutamine Across Different Subpopulations and Correlation with Adverse Events.
Mak, C; Poola, N; Tseng, J; Vilchez, RA; Wang, X, 2021
)
0.62
"Phenylacetic acid and phenylacetylglutamine (PAGN) pharmacokinetic data and adverse events from five clinical studies were included in the analysis."( Exposures of Phenylacetic Acid and Phenylacetylglutamine Across Different Subpopulations and Correlation with Adverse Events.
Mak, C; Poola, N; Tseng, J; Vilchez, RA; Wang, X, 2021
)
0.62
" No correlation was observed between PAA plasma exposure and neurologic adverse events in patients with stable cirrhosis or acute hepatic encephalopathy."( Exposures of Phenylacetic Acid and Phenylacetylglutamine Across Different Subpopulations and Correlation with Adverse Events.
Mak, C; Poola, N; Tseng, J; Vilchez, RA; Wang, X, 2021
)
0.62
" Phenylacetic acid plasma exposure was not correlated with neurologic adverse events in the ornithine phenylacetate target patient population."( Exposures of Phenylacetic Acid and Phenylacetylglutamine Across Different Subpopulations and Correlation with Adverse Events.
Mak, C; Poola, N; Tseng, J; Vilchez, RA; Wang, X, 2021
)
0.62
" Safety outcomes included adverse events and standard laboratory assessments."( Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease.
Baum, SJ; Chakravarthy, MV; Chera, H; Gunn, NT; Harrison, SA; Kohli, A; Koziel, MJ; Patil, R; Younes, ZH; Zhao, J, 2021
)
0.62
" Study products were safe and well tolerated with stable lipid and weight profiles."( Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease.
Baum, SJ; Chakravarthy, MV; Chera, H; Gunn, NT; Harrison, SA; Kohli, A; Koziel, MJ; Patil, R; Younes, ZH; Zhao, J, 2021
)
0.62
" However, there still exist some problems including drug side effects, adverse cardiac events after percutaneous coronary intervention."( Efficacy and safety of Guhong injection for coronary heart disease: A protocol for systematic review and meta-analysis.
Che, S; Liu, L; Shi, G; Wang, M; Zhang, S, 2021
)
0.62
" Further research is necessary to elucidate effects of high doses and long-term consumption of amino acid supplements on immune system, brain function, muscle protein balance, synthesis of toxic metabolites, and tumor growth and examine their suitability under certain circumstances."( Side effects of amino acid supplements.
Holeček, M, 2022
)
0.72
" Treatment-emergent adverse event (TEAE) rates were similar between arms."( Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial.
Agarwal, N; Akella, L; Appleman, LJ; Davis, N; Escudier, B; Figlin, R; Gandhi, S; Geynisman, DM; Goodman, O; Iacovelli, R; Jain, RK; Lawrence, NJ; Lee, RJ; McGregor, B; Mellado, B; Motzer, R; Orford, K; Porta, C; Powles, T; Sepúlveda Sánchez, JM; Stadler, WM; Tannir, NM, 2022
)
0.72
" This study aimed to investigate how serum diamine oxidase (DAO) activity affects antitumor effects, adverse events, and amino acid absorption."( Serum diamine oxidase activity derived from response to chemotherapy affects adverse events and serum amino acid levels.
Imai, T; Matsuhashi, N; Okumura, N; Sato, Y; Shimokawa, T; Takahashi, T; Tanaka, Y; Yoshida, K, 2022
)
0.72
" Additionally, we compared adverse events, inflammatory markers, blood amino acid levels, and quality of life between the high and low DAO activity groups during chemotherapy."( Serum diamine oxidase activity derived from response to chemotherapy affects adverse events and serum amino acid levels.
Imai, T; Matsuhashi, N; Okumura, N; Sato, Y; Shimokawa, T; Takahashi, T; Tanaka, Y; Yoshida, K, 2022
)
0.72
" The absorption capacity of amino acids was maintained in the group with high DAO activity, which may have contributed to the anti-inflammatory effect and provided a background for reducing adverse events."( Serum diamine oxidase activity derived from response to chemotherapy affects adverse events and serum amino acid levels.
Imai, T; Matsuhashi, N; Okumura, N; Sato, Y; Shimokawa, T; Takahashi, T; Tanaka, Y; Yoshida, K, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
"In order to explain the long-term therapeutic activity of (+/-)-4-benzamide-N,-di-n-propylglutaramic acid (proglumide, Milid) a pharmacokinetic study was carried out in rats by three administration routes."( Pharmacokinetic approach to proglumide long-term activity.
Bignamini, AA; Casula, PL; Rovati, AL, 1979
)
0.26
" The pharmacokinetics of loxiglumide in plasma after the first single dose of 400 mg is characterized by a lag time of 16 +/- 4 min, a rapid invasion (kinv = 10 h-1), a Cmax of 11."( Pharmacokinetics and tolerance of repeated oral doses of loxiglumide.
Chisté, R; Giacovelli, G; Rovati, LC; Setnikar, I, 1989
)
0.28
" infusion the plasma levels were consistent with an open two-compartment pharmacokinetic model represented by the equation C (mg/l) = 43."( Pharmacokinetics of loxiglumide after single intravenous or oral doses in man.
Chisté, R; Makovec, F; Rovati, LC; Setnikar, I; Warrington, SJ, 1988
)
0.27
" There was no significant difference in methotrexate volume of distribution or half-life between the two groups."( A significant methotrexate-glutamine pharmacokinetic interaction.
Bartlett, DL; Charland, SL; Torosian, MH,
)
0.13
" The two products were found bioequivalent with regard to the release of fluoride, both on the basis of the AUC and Cmax of fluoride in plasma and of the urinary excretion of fluoride during the 48 h following the administration."( Bioavailability and pharmacokinetics of fluoride from two glutamine monofluorophosphate preparations.
Setnikar, I; Warneke, G, 1993
)
0.29
" The pharmacokinetic behaviour of the various active ingredients was examined at a haematic level."( Pharmacokinetic study of the relative bioavailability and bioequivalence after oral intensive or repeated short term treatment with two polyamino acid formulations.
Castana, R; Insirello, L; Leonardi, G; Matera, M, 1993
)
0.29
" Dengue patients manifested the same pharmacokinetic responses to a 20 g Ala-Gln bolus as healthy controls."( The pharmacokinetic responses of humans to 20 g of alanyl-glutamine dipeptide differ with the dosing protocol but not with gastric acidity or in patients with acute Dengue fever.
Fürst, P; Klassen, P; Mazariegos, M; Solomons, NW, 2000
)
0.31
" We performed a pharmacokinetic study, as part of a phase I trial, of PAA in children with refractory cancer."( Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer.
Adamson, P; Aiken, A; Balis, F; Berg, S; Blaney, SM; Jakacki, R; Klenke, R; Murry, DJ; Packer, R; Serabe, BM; Thompson, P, 2003
)
0.32
"The capacity-limited conversion of PAA to PAG has important implications for the dosing of PAA, and the pharmacokinetic model described here may be useful for individualizing the infusion rate of the drug in future clinical trials."( Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer.
Adamson, P; Aiken, A; Balis, F; Berg, S; Blaney, SM; Jakacki, R; Klenke, R; Murry, DJ; Packer, R; Serabe, BM; Thompson, P, 2003
)
0.32
"To our knowledge, this is the first reported pharmacokinetic study on an IED even though these products have been on the market for 20 years."( Increasing plasma glutamine in postoperative patients fed an arginine-rich immune-enhancing diet--a pharmacokinetic randomized controlled study.
Arnaud-Battandier, F; Curis, E; Cynober, L; Delpierre, E; Loï, C; Neveux, N; Niddam, C; Zazzo, JF, 2009
)
0.35
" Additional investigations into the posology and pharmacokinetic profile of selenium are still required."( Selenium supplementation in the critically ill: posology and pharmacokinetics.
Hardy, G; Manzanares, W, 2009
)
0.35
" However, pronounced interpatient variability, differences in pharmacokinetic properties between asparaginases and the formation of asparaginase antibodies make it difficult to predict the degree of asparagine depletion that will result from a given dose of asparaginase."( Asparaginase pharmacokinetics and implications of therapeutic drug monitoring.
Asselin, B; Rizzari, C, 2015
)
0.42
"To investigate the pharmacokinetic characteristics of active constituents of Guhong injection in rats with cerebral ischemia reperfusion injury."( [Pharmacokinetics of main activ ingredients of Guhong injection in cerebral ischemia rats].
Fang, YC; He, Y; Wan, HT; Yang, JH; Yin, F; Yu, L; Zhou, HF, 2018
)
0.48
" Based on pharmacokinetic parameters determined in this study and targeting a blood concentration >16 μg/mL for 24 h, an intravenous dose >1 g/kg would be needed, making the use of this drug unrealistic."( In vitro susceptibility testing for the emerging pathogenic mould Veronaea botryosa and pharmacokinetic parameters of natamycin in white sturgeon (Acipenser transmontanus).
Coleman, D; Kenelty, K; Knych, H; Martínez-López, B; Soto, E; Tomasi, V; Yun, S, 2022
)
0.72

Compound-Compound Interactions

Study was to investigate the effects of parenteral glutamine (GLN) supplementation in combination with enteral nutrition (EN) on intestinal mucosal immunity in septic rats by cecal ligation and puncture.

ExcerptReferenceRelevance
"A double-blind placebo controlled trial was carried out in 32 hospitalized patients with various rheumatic disorders to assess the therapeutic effectiveness and gastric tolerance of indomethacin (150 mg/day) used alone or in combination with proglumide (900 mg/day)."( Double-blind comparison of the antirheumatic activity and gastric side-effects of indomethacin used alone or in combination with a gastro-protective agent, proglumide.
Pipitone, V, 1976
)
0.26
" The antitumour effects of interferon alpha (IFN alpha) in combination with AS2-1, the hydrolysis product of 3-phenylacetyl-amino-2,6-piperidinedione, were examined using several human tumour cell lines as a model."( Interferon in combination with antitumourigenic phenyl derivatives: potentiation of IFN alpha activity in-vitro.
Samid, D; Shack, S; Yeh, TJ, 1991
)
0.28
"The purpose of this study was to assess the effect of oral glutamine supplementation combined with resistance training in young adults."( Effect of glutamine supplementation combined with resistance training in young adults.
Burke, DG; Candow, DG; Chilibeck, PD; Davison, KS; Smith-Palmer, T, 2001
)
0.31
" I show how such biochemical information may be combined with genetic information, thus demonstrating the usefulness of biochemical data."( Biochemical data in ornithine transcarbamylase deficiency (OTCD) carrier risk estimation: logistic discrimination and combination with genetic information.
Oexle, K, 2006
)
0.33
"To investigate the effect of oral glutamine alone or combined with short chain fatty acids (SCFA) in the intestinal adaptation of rats submitted to an massive enterectomy."( Glutamine alone or combined with short-chain fatty acids fails to enhance gut adaptation after massive enterectomy in rats.
Aguilar-Nascimento, JE; Bicudo, AS; Cavalcanti, RN; Gomes-da-Silva, MH; Nascimento, M; Neves, Jde S; Nochi, RJ, 2006
)
0.33
"After receiving 70% small bowel resection, 30 Wistar rats were randomized to received either standard rat chow (control group, n=10) or the same diet supplemented with 3,05% of glutamine alone (glutamine group, n=10) or combined with a solution containing SCFA (glutamine+SCFA group, n=10)."( Glutamine alone or combined with short-chain fatty acids fails to enhance gut adaptation after massive enterectomy in rats.
Aguilar-Nascimento, JE; Bicudo, AS; Cavalcanti, RN; Gomes-da-Silva, MH; Nascimento, M; Neves, Jde S; Nochi, RJ, 2006
)
0.33
"To examine the functional significance of 12-LOX 261 Arg> Gln polymorphism and its association, alone and in combination with COX-2 -1195G > A and -765G > C polymorphisms, with risk of developing esophageal squamous cell carcinoma (ESCC)."( Platelet 12-lipoxygenase Arg261Gln polymorphism: functional characterization and association with risk of esophageal squamous cell carcinoma in combination with COX-2 polymorphisms.
Guo, Y; Lin, D; Miao, X; Sun, T; Tan, W; Zhang, X; Zhao, D, 2007
)
0.34
" Although short-term exercise (10 days) alone did not produce beneficial effects that would reduce tumor damage, host protein metabolism was improved when exercise was combined with a leucine-rich diet."( Light aerobic physical exercise in combination with leucine and/or glutamine-rich diet can improve the body composition and muscle protein metabolism in young tumor-bearing rats.
Gomes-Marcondes, MC; Salomão, EM, 2012
)
0.38
"To observe the effects of glutamine combined with ulinastatin on inflammatory response of patients with severe burn injury."( [Effects of glutamine combined with ulinastatin on inflammatory response of patients with severe burn injury].
Deng, XD; Mao, XF; Sun, SG; Sun, Y; Wang, LX; Zhang, P; Zhou, YF, 2013
)
0.39
"Sixty patients with severe burn injury admitted to our burn wards from January 2010 to December 2011 conforming to the study criteria were divided into control group (C, n = 20), glutamine group (G, n = 20), and glutamine combined with ulinastatin group (G + U, n = 20) according to the random number table."( [Effects of glutamine combined with ulinastatin on inflammatory response of patients with severe burn injury].
Deng, XD; Mao, XF; Sun, SG; Sun, Y; Wang, LX; Zhang, P; Zhou, YF, 2013
)
0.39
"Glutamine combined with ulinastatin treatment can alleviate damage to intestine after severe burn injury, lower the serum level of inflammatory cytokines, promote wound healing, and reduce the incidence of burn sepsis."( [Effects of glutamine combined with ulinastatin on inflammatory response of patients with severe burn injury].
Deng, XD; Mao, XF; Sun, SG; Sun, Y; Wang, LX; Zhang, P; Zhou, YF, 2013
)
0.39
"Taken together, these findings reveal the benefits of glutamine alone or in combination with other gut-trophic nutrients in growing children via interactions with leptin."( Effects of glutamine alone or in combination with zinc and vitamin A on growth, intestinal barrier function, stress and satiety-related hormones in Brazilian shantytown children.
Anstead, GM; Figueiredo, ÍL; Guerrant, RL; Lima, AA; Lima, NL; Mota, RM; Oriá, RB; Soares, AM; Zhang, Q, 2014
)
0.4
" The aim of this study was to investigate the effects of parenteral glutamine (GLN) supplementation in combination with enteral nutrition (EN) on intestinal mucosal immunity in septic rats by cecal ligation and puncture (CLP)."( Parenteral glutamine supplementation in combination with enteral nutrition improves intestinal immunity in septic rats.
Fan, J; Li, G; Meng, Q; Sheng, Z; Tao, S; Wang, W; Wu, L, 2015
)
0.42
"The results of this study show that parenteral glutamine supplementation in combination with enteral nutrition may attenuate PP apoptosis, increase PP cell yield and intestinal lamina propria IgA plasma cells, and subsequently improve intestinal mucosal immunity."( Parenteral glutamine supplementation in combination with enteral nutrition improves intestinal immunity in septic rats.
Fan, J; Li, G; Meng, Q; Sheng, Z; Tao, S; Wang, W; Wu, L, 2015
)
0.42
"The aim of this study is to investigate the effects of parenteral glutamine(GLN) supplementation combined with enteral nutrition (EN) on heat shock protein 90(Hsp90) expression, apoptosis of lymphoid organs and circulating lymphocytes, immunological function and survival in severely burned rats."( Effect of parenteral glutamine supplementation combined with enteral nutrition on Hsp90 expression and lymphoid organ apoptosis in severely burned rats.
Chen, X; Fan, J; Li, GP; Meng, QY; Wu, J; Wu, LD; Xiong, M, 2016
)
0.43
"The results revealed that parenteral GLN supplementation combined with EN significantly increased the GLN concentrations of plasma and tissues, the serum immunoglobulin content, the circulating lymphocyte number, the CD4/CD8 ratio, the indexes of thymus and spleen, NPI and survival as compared with the burn+EN+AA group (p<0."( Effect of parenteral glutamine supplementation combined with enteral nutrition on Hsp90 expression and lymphoid organ apoptosis in severely burned rats.
Chen, X; Fan, J; Li, GP; Meng, QY; Wu, J; Wu, LD; Xiong, M, 2016
)
0.43
"The results of this study show that parenteral GLN supplementation combined with EN may increase the GLN concentrations of plasma and tissues, up-regulate the expression of Hsp90, attenuate apoptosis in lymphoid organ and circulating lymphocyte, enhance the immunological function and improve survival in severely burned rats."( Effect of parenteral glutamine supplementation combined with enteral nutrition on Hsp90 expression and lymphoid organ apoptosis in severely burned rats.
Chen, X; Fan, J; Li, GP; Meng, QY; Wu, J; Wu, LD; Xiong, M, 2016
)
0.43
"To compare the effectiveness of the phosphodiesterase type 5 inhibitor (PDE-5i) tadalafil alone and in combination with a biologically active dietary supplement (BADS) NeyroDoz, containing the precursors of serotonin in patients with erectile dysfunction (ED) associated with secondary premature ejaculation (SPE)."( [New data on the effectiveness of Tadalafil alone and in combination with NeyroDoz in treating erectile dysfunction associated with secondary premature ejaculation].
Akhvlediani, ND; Matyukhov, IP, 2016
)
0.43
"The aim of this study was to investigate the effects of parenteral glutamine (GLN) supplementation combined with enteral nutrition (EN) on heat shock protein (Hsp) 90 expression and Peyer's patch (PP) apoptosis in severely burned rats."( Effect of parenteral glutamine supplementation combined with enteral nutrition on Hsp90 expression and Peyer's patch apoptosis in severely burned rats.
Chen, X; Cheng, B; Fan, J; Meng, QY; Tao, SY; Wang, W; Wang, YB; Wu, J; Wu, LD; Zeng, P, 2018
)
0.48
"The results of this study show that parenteral glutamine supplementation combined with EN may upregulate the expression of Hsp90, reduce caspase-3 activity, lessen the release of proinflammatory cytokines, attenuate PP apoptosis, and improve intestinal IgA response in burned rats."( Effect of parenteral glutamine supplementation combined with enteral nutrition on Hsp90 expression and Peyer's patch apoptosis in severely burned rats.
Chen, X; Cheng, B; Fan, J; Meng, QY; Tao, SY; Wang, W; Wang, YB; Wu, J; Wu, LD; Zeng, P, 2018
)
0.48
"EN combined with glutamine may effectively improve nutritional status after IPAA."( Enteral nutrition combined with glutamine promotes recovery after ileal pouch-anal anastomosis in rats.
He, AQ; Li, KY; Liu, G; Liu, J; Liu, T; Xu, YY, 2018
)
0.48
" Cultivar 'Pingan 8' showed lower Zn concentrations in the grain than did cultivar 'Yangao 006' after nitrogen (N) combined with Zn application."( Effects of nitrogen combined with zinc application on glutamate, glutamine, aspartate and asparagine accumulation in two winter wheat cultivars.
Gao, W; Liu, H; Nie, Z; Rengel, Z; Wang, J; Zhao, P, 2018
)
0.48
" First, ARTP mutagenesis combined with high-throughput screening generated an l-glutamine-producing strain of Corynebacterium glutamicum with titer of 25."( Enhancing l-glutamine production in Corynebacterium glutamicum by rational metabolic engineering combined with a two-stage pH control strategy.
Hu, M; Liu, F; Lv, Q; Rao, Z; Tian, L; Wang, Q; Xu, M, 2021
)
0.62
"The aim of this study was to explore the efficacy of imipenem combined with glutamine in the treatment of severe acute pancreatitis with abdominal infection in mainland China using meta-analysis."( Effects of imipenem combined with glutamine in the treatment of severe acute pancreatitis with abdominal infection in mainland China: a meta-analysis.
He, C; Jin, LR; Zhou, S, 2022
)
0.72
"We searched China National Knowledge Network, Wanfang Medical Network, Chinese Science Citation Database, PubMed, and Embase Databases for publications of imipenem combined with glutamine in the treatment of severe acute pancreatitis abdominal infection."( Effects of imipenem combined with glutamine in the treatment of severe acute pancreatitis with abdominal infection in mainland China: a meta-analysis.
He, C; Jin, LR; Zhou, S, 2022
)
0.72
" Meta-analysis results showed that the efficacy of imipenem combined with glutamine in the treatment of severe acute pancreatitis with abdominal infection was significantly better than that of imipenem alone (odds ratio=0."( Effects of imipenem combined with glutamine in the treatment of severe acute pancreatitis with abdominal infection in mainland China: a meta-analysis.
He, C; Jin, LR; Zhou, S, 2022
)
0.72
"Imipenem combined with glutamine can significantly improve the efficacy in the treatment of severe acute pancreatitis with abdominal cavity infection."( Effects of imipenem combined with glutamine in the treatment of severe acute pancreatitis with abdominal infection in mainland China: a meta-analysis.
He, C; Jin, LR; Zhou, S, 2022
)
0.72
" In summary, the results demonstrate that pyruvate metabolism acts as novel targetable metabolic vulnerabilities for HCC treatment in combination with a glutamine-deficient diet."( Genome-Wide CRISPR/Cas9 Library Screening Revealed Dietary Restriction of Glutamine in Combination with Inhibition of Pyruvate Metabolism as Effective Liver Cancer Treatment.
Bao, MH; Chan, CY; Chen, Y; Lee, D; Tse, AP; Wei, L; Wong, BP; Wong, CC; Yang, C; Yuen, VW; Zhang, MS, 2022
)
0.72
"Objective To investigate the effect of dexamethasone (DEX) combined with glutamine (Gln) on lung inflammation and pulmonary edema in rats with acute lung injury induced by lipopolysaccharide (LPS) and its related mechanisms."( [Mechanism of dexamethasone combined with glutamine in reducing lung inflammation and pulmonary edema in rats with acute lung injury].
He, H; Kou, Y; Shi, J; Wang, R; Wang, X,
)
0.13

Bioavailability

The authors studied the relative bioequivalence and bioavailability of two oral polyamino-acid formulations (packet and flacon) based on 4 amino acids. The aim of this study was to explore the effect of repeated maternal alcohol exposure and L-glutamine supplementation on fetal growth and amino acid bioavailability.

ExcerptReferenceRelevance
" This compound proved to have limited bioavailability (1% in rats) due to cleavage of the serine ester bond and rapid hepatic extraction."( Highly potent, orally active diester macrocyclic human renin inhibitors.
Ball, RG; Colletti, AE; Doyle, JJ; Halgren, TA; Krieter, PA; Schorn, TW; Stearns, RA; Steiner, MG; Tata, JR; Weber, AE, 1992
)
0.28
") also decreased basal cGMP levels in mouse cerebellum for up to 3 h, a result suggesting brain bioavailability and a long duration of NMDA receptor antagonism in vivo."( Neurochemical interactions of competitive N-methyl-D-aspartate antagonists with dopaminergic neurotransmission and the cerebellar cyclic GMP system: functional evidence for a phasic glutamatergic control of the nigrostriatal dopaminergic pathway.
Cler, JA; Contreras, PC; Emmett, MR; Farah, JM; Iyengar, S; Mick, SJ; Rao, TS; Wood, PL, 1991
)
0.28
" Amino acids thus increased bioavailability by displacing zinc bound to albumin."( Effect of taurine, L-glutamine and L-histidine addition in an amino acid glucose solution on the cellular bioavailability of zinc.
Faure, H; Favier, A; Fussellier, M; Guiraud, P; Harraki, B; Richard, MJ; Rochat, MH, 1994
)
0.29
"A two-way cross-over study was conducted on 12 Caucasian male healthy volunteers aged between 25 and 38 years in order to determine the bioavailability and pharmacokinetics of fluoride after single oral administration in fasting conditions of two products (tablets and powder for oral use) of L-glutamine monofluorophosphate (G-MFP, CAS 116420-36-1)."( Bioavailability and pharmacokinetics of fluoride from two glutamine monofluorophosphate preparations.
Setnikar, I; Warneke, G, 1993
)
0.29
" A therapeutic application of the present results is that if bioavailability of orally administered peptidomimetic drugs is limited, patients may be tried on a high-protein diet to enhance their absorption."( Mechanism of dipeptide stimulation of its own transport in a human intestinal cell line.
Adibi, SA; Bawani, SZ; Thamotharan, M; Zhou, X,
)
0.13
" Limited bioavailability of glutamine may affect arginine synthesis, which may have consequences for nitric oxide (NO) synthesis."( Renal amino acid metabolism during endotoxemia in the rat.
Cobben, DC; Dejong, CH; Deutz, NE; Hallemeesch, MM; Soeters, PB, 2000
)
0.31
" bioavailability determination."( A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies.
Baker, SD; Bowling, MK; Carducci, MA; Donehower, RC; Figg, WD; Gilbert, J; Grochow, L; Zabelina, Y, 2001
)
0.31
" We have hypothesized that mitochondrial lysine degradation is regulated by bioavailability of 2-oxoglutarate in the same compartment, and our studies in physiologic fluid derived from patients with the above described disorders supports our hypothsis."( Plasma lysine concentration and availability of 2-ketoglutarate in liver mitochondria.
Kamoun, P; Rabier, D; Richard, V; Saudubray, JM, 2002
)
0.31
" In conclusion, the combinatorial use of C12 with Tau or L-Gln could lead to a novel formulation improving the bioavailability of poorly absorbable drugs without any serious local damages."( Combinatorial use of sodium laurate with taurine or L-glutamine enhances colonic absorption of rebamipide, poorly absorbable antiulcer drug, without any serious histopathological mucosal damages.
Higaki, K; Kimura, T; Minami, T; Miyake, M; Odomi, M; Ogawara, K; Oka, Y; Toguchi, H, 2003
)
0.32
"Sepsis considerably alters the intestinal barrier functions, which in turn modify the absorption and bioavailability of nutrients."( Endotoxemia affects citrulline, arginine and glutamine bioavailability.
Arnaud, P; Chaumeil, JC; Curis, E; Cynober, L; Elwafi, F; Moinard, C; Neveux, N; Zerrouk, N, 2012
)
0.38
"Endotoxemia affects the bioavailability of AAs differently according to the amino acid considered."( Endotoxemia affects citrulline, arginine and glutamine bioavailability.
Arnaud, P; Chaumeil, JC; Curis, E; Cynober, L; Elwafi, F; Moinard, C; Neveux, N; Zerrouk, N, 2012
)
0.38
"Catabolism of amino acids (AA) by intestinal bacteria greatly affects their bioavailability in the systemic circulation and the health of animals and humans."( L-Glutamine regulates amino acid utilization by intestinal bacteria.
Dai, ZL; Li, XL; Wu, G; Xi, PB; Zhang, J; Zhu, WY, 2013
)
0.39
" inducible nitric oxide synthase (iNOS) and arginase (ARG1), which metabolize the semi-essential amino acid L-arginine (L-Arg) whose bioavailability is crucial for T-cell proliferation and functions."( L-glutamine is a key parameter in the immunosuppression phenomenon.
Bronte, V; Chen, J; DeCrescenzo, G; Hammami, I; Jolicoeur, M, 2012
)
0.38
" Other dietary components, such as poorly absorbed short-chain carbohydrate, polyols, and exogenous microparticles, also participate in the etiopathogenesis of IBD."( Nutritional treatment in inflammatory bowel disease. An update.
González-Castillo, S; Guagnozzi, D; Lucendo, AJ; Olveira, A, 2012
)
0.38
" The aim of this study was to explore the effect of repeated maternal alcohol exposure and L-glutamine supplementation on fetal growth and amino acid bioavailability during the third trimester-equivalent period in an ovine model."( Maternal L-glutamine supplementation prevents prenatal alcohol exposure-induced fetal growth restriction in an ovine model.
Sawant, OB; Washburn, SE; Wu, G, 2015
)
0.42
" Inhibition of glutaminase by allosteric GLS inhibitor bis-2-(5-phenylacetamido-1, 2, 4-thiadiazol-2-yl) ethyl sulfide or by novel, potent, orally bioavailable GLS inhibitor CB-839 reduced intracellular glutamate levels and inhibited growth of AML cells."( Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.
Baran, N; Cai, T; Chan, SM; Davis, RE; DiNardo, C; Flores, ER; Gonzalez, D; Haferlach, T; Jacamo, R; Konoplev, S; Konopleva, M; Li, W; Lodi, A; Ma, H; Majeti, R; Matre, P; Qi, Y; Samudio, I; Schimmer, AD; Su, X; Sweeney, SR; Tiziani, S; Velez, J; Wang, T, 2016
)
0.43
" Low arginine bioavailability plays a pivotal role in the pathogenesis of a growing number of varied diseases, including sickle cell disease, thalassemia, malaria, acute asthma, cystic fibrosis, pulmonary hypertension, cardiovascular disease, certain cancers, and trauma, among others."( Acquired Amino Acid Deficiencies: A Focus on Arginine and Glutamine.
Hamilton-Reeves, J; Martindale, RG; Morris, CR; Ochoa Gautier, JB; Sarav, M, 2017
)
0.46
" We investigated glutamine dependence of MPNST using JHU395, a novel orally bioavailable GA prodrug designed to circulate inert in plasma, but permeate and release active GA within target tissues."( The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor.
Aguilar, JMH; Alt, J; Blakeley, JO; Brayton, C; Dash, RP; Lam, J; Lemberg, KM; Majer, P; Nedelcovych, MT; Rais, R; Rodriguez, C; Slusher, BS; Tenora, L; Veeravalli, V; Wu, Y; Zhao, L, 2020
)
0.56
" In contrast to previous studies, treatment of autochthonous tumour-bearing animals with Telaglenastat (CB-839), an orally bioavailable GLS inhibitor, successfully inhibits undifferentiated pleomorphic sarcoma (UPS) tumour growth."( Targeting glutamine metabolism slows soft tissue sarcoma growth.
Burrows, M; Finan, JM; Gade, TPF; Gong, YY; Huangyang, P; Khare, S; Lee, P; Malik, D; Nissim, I; Perkons, N; Rhoades, S; Simon, MC; Weljie, AM, 2020
)
0.56
" CB-839 is a potent, selective, orally bioavailable inhibitor of glutaminase that has activity in Triple receptor-Negative Breast Cancer (TNBC) cell lines and evidence of efficacy in advanced TNBC patients."( Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer.
Baguley, BC; Dechaume, AL; Katt, WP; Leung, EY; Murray, PM; Singleton, DC, 2020
)
0.56
" Glutamine and glutamine-related amino acids play a key role in fetal development and are known to alter the mTOR pathway; recent research has shown that disturbances in their bioavailability and signaling pathways may mediate adverse effects of prenatal alcohol exposure."( Prenatal alcohol exposure and maternal glutamine supplementation alter the mTOR signaling pathway in ovine fetal cerebellum and skeletal muscle.
Meng, C; Sawant, OB; Washburn, SE; Wu, G, 2020
)
0.56
" In the central nervous system (CNS), glutamine metabolism is particularly relevant, because the glutamine-glutamate cycle is a way of controlling the production of glutamate-derived neurotransmitters by tightly regulating the bioavailability of the amino acids in a neuron-astrocyte metabolic symbiosis-dependent manner."( Take Advantage of Glutamine Anaplerosis, the Kernel of the Metabolic Rewiring in Malignant Gliomas.
Gonçalves, LG; Martins, F; Pojo, M; Serpa, J, 2020
)
0.56
" However, these inhibitors have variable efficacy, specificity and bioavailability in research and clinical settings, implying the need for novel and improved GLS inhibitors."( Identification and characterization of a novel glutaminase inhibitor.
Cederkvist, H; Kolan, SS; Sener, Z; Skålhegg, BS; Wik, JA, 2022
)
0.72
" We found that RCC cells are highly dependent on glutamine for proliferation, and this dependence strongly correlated with sensitivity to telaglenstat (CB-839), an investigational, first-in-class, selective, orally bioavailable GLS inhibitor."( The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.
Chen, J; Dang, R; Emberley, E; Gross, M; Huang, T; Li, W; MacKinnon, A; Pan, A; Parlati, F; Singh, D; Sotirovska, N; Steggerda, SM; Wang, T, 2021
)
0.62
"Oral glutamine supplementation acutely improved glutamine and arginine bioavailability in both plasma and erythrocytes."( Implications for the metabolic fate of oral glutamine supplementation within plasma and erythrocytes of patients with sickle cell disease: A pharmacokinetics study.
Hagar, R; Kuypers, FA; Larkin, S; Lavrisha, L; Morris, CR; Saulys, A; Suh, JH; Vichinsky, EP, 2022
)
0.72
" after a cocktail of poorly absorbed antibiotics to suppress gut microbiota."( Atlas of gut microbe-derived products from aromatic amino acids and risk of cardiovascular morbidity and mortality.
Bäckhed, F; Buffa, JA; Demuth, I; Fischbach, MA; Haghikia, A; Hazen, SL; König, M; Landmesser, U; Li, L; Li, XS; Nemet, I; Romano, KA; Steinhagen-Thiessen, E; Tang, WHW; Wilcox, J; Witkowski, M, 2023
)
0.91

Dosage Studied

UCD patients (n=26) ages 2months through 17years were treated with GPB and sodium phenylbutyrate (NaPBA) in two short-term, open-label crossover studies. Threshold responses were observed at 100 microM glutamine, and the dose-response relation did not show inflection or saturation at concentratio.

ExcerptRelevanceReference
"An oral dosing of either acetylsalicylic acid (ASA) or taurocholic acid (TCA) to pylorus-ligated rats subjected to water-immersion stress produced severe damage to the gastric musoca in contrast to the irritation observed in non-stressed ones."( Effects of L-glutamine of acetylsalicylic acid or taurocholic acid-induced gastric lesions and secretory changes in pylorus-ligated rats under normal or stress conditions.
Hung, CR; Okabe, S; Takagi, K; Takeuchi, K, 1976
)
0.26
" Gross bleeding from the pouch treated with ASA was never observed with the concomitant dosing of ASA and L-glutamine 50 or 100 mM."( Effects of L-glutamine on acetylsalycylic acid induced gastric lesions and acid back diffusion in dogs.
Hung, CR; Murata, T; Okabe, S; Takagi, K; Takeuchi, K, 1976
)
0.26
" The effects on the amino acids are not due to a change in the food intake caused by dosing with arsenate."( The effects of sodium arsenate on the free amino acid levels in erythrocytes and plasma in rats.
Kilroe-Smith, TA; McLoughlin, JL, 1979
)
0.26
" Since human pharmacokinetics was found to be rather similar to that in rats, it can be extrapolated that steady state plasma level of drug during therapeutic dosage regimen should range around 60% of peak level of single administration."( Pharmacokinetic approach to proglumide long-term activity.
Bignamini, AA; Casula, PL; Rovati, AL, 1979
)
0.26
"Hyperbolic and allosteric mathematical equations are used extensively to describe cumulative dose-response curves in pharmacology."( Mathematical dose-response model for sodium cotransport with glucose and glutamine in the rabbit ileal mucosa.
Freire Júnior, JE; Lima, AA; Soares, AM, 1992
)
0.28
" The dose-response curves of these substrates suggest that the intestinal cotransport kinetics for glutamine is different from that of glucose and alanine."( Transport of glutamine, alanine and glucose by rabbit intestinal membrane.
Freire Júnior, JE; Lima, AA; Soares, AM, 1991
)
0.28
"A series of dose-response studies was conducted to evaluate the clinical safety, pharmacokinetics, and metabolic effects of L-glutamine administered to humans."( Safety and metabolic effects of L-glutamine administration in humans.
Benfell, K; Brown, E; Ferrari-Baliviera, E; Lowe, DK; Smith, RJ; Wilmore, DW; Young, LS; Ziegler, TR,
)
0.13
" Proglumide both shifted the dose-response curve for morphine analgesia to the left and prolonged morphine's duration of action."( Proglumide selectively potentiates supraspinal mu 1 opioid analgesia in mice.
Bodnar, RJ; Pasternak, GW; Paul, D, 1990
)
0.28
" CR 1409 caused a rightward and parallel shift in the dose-response curve of CCK-8-stimulated pancreatic protein secretion in anesthetized rats, demonstrating a competitive mechanism of inhibition."( The effect of CR 1409, a potent CCK receptor antagonist, on basal and stimulated pancreatic secretion in rat.
Nagy, I; Pap, A; Takács, T; Varró, V, 1990
)
0.28
" The model was used to demonstrate a dose-response curve to bolus administration of exogenous cholecystokinin (0."( In vivo comparison of inhibition with proglumide and CR-1409 of cholecystokinin-induced pressure in the biliary tract of the guinea pig.
Hashimoto, T; MacLellan, DG; Poston, GJ; Thompson, JC; Townsend, CM; Upp, JR, 1990
)
0.28
" Biphasic dose-response curves to cholecystokinin for amylase release shifted to the right with an increase in the concentration of the drug."( CR-1409: a potent inhibitor of cholecystokinin-stimulated amylase release and cholecystokinin binding in rat pancreatic acini.
Iwamoto, Y; Kuzuya, T; Yamamoto, R, 1987
)
0.27
" Loxiglumide caused a concentration-dependent rightward shift of the dose-response curve for CCK-8-stimulated amylase release without altering the maximal response."( [Inhibitory effect of a new proglumide derivative, loxiglumide, on CCK action in isolated rat pancreatic acini].
Baba, S; Fujii, M; Fujisawa, T; Koide, M; Nakamura, T; Okabayashi, Y; Otsuki, M; Tani, S, 1989
)
0.28
" In the isolated acini, CR 1392 caused a parallel rightward shift of the dose-response curve for amylase secretion stimulated by cholecystokinin octapeptide (CCK-8)."( Effects of a new proglumide analogue CR 1392 on pancreatic exocrine secretion in the rat.
Baba, S; Fujii, M; Fujisawa, T; Koide, M; Nakamura, T; Okabayashi, Y; Otsuki, M; Tani, S, 1989
)
0.28
" There was no dose-response effect of sulpiride on serum levels of the monoamine metabolites or the amino acids."( Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment.
Alfredsson, G; Wiesel, FA, 1989
)
0.28
" Furthermore, the infusion of glutamine peptides caused a significant increase in intracellular glutamine levels; however, the dosage of glutamine peptides was too low to normalize the muscular glutamine concentrations."( Infusion of dipeptides as nutritional substrates for glutamine, tyrosine, and branched-chain amino acids in patients with acute pancreatitis.
Karner, J; Langer, K; Roth, E; Steininger, R, 1989
)
0.28
" We conclude that the duration and dosage of glutamine administration (equivalent to 26 gm glutamine per day in a patient weighing 70 kg) used in this study are not sufficient to restore glutamine deficiency of the skeletal muscle in the depleted state."( Glutamine-containing dipeptides as infusion substrates in the septic state.
Fürst, P; Karner, J; Ollenschläger, G; Roth, E; Simmel, A, 1989
)
0.28
" To investigate the dose-response effects of glutamine, further studies were performed using isonitrogenous and isocaloric solutions containing 0, 2, and 3 g of glutamine/100 ml."( Maintenance of small bowel mucosa with glutamine-enriched parenteral nutrition.
Hwang, TL; O'Dwyer, ST; Smith, RJ; Wilmore, DW,
)
0.13
" Threshold responses were observed at 100 microM glutamine, and the dose-response relation did not show inflection or saturation at concentrations of up to 10 mM."( NMDA receptor activation by residual glutamate in glutamine preparations: a cautionary note regarding weak NMDA receptor agonists.
Barish, ME; Sands, SB, 1989
)
0.28
" Atropine shifted the dose-response curve of CCK-OP in pylorus, duodenum and antrum to the right suggesting a neural action of CCK-OP."( Effect of the novel cholecystokinin receptor antagonist CR-1392 on cholecystokinin-induced antroduodenal and pyloric motor activity in vivo.
Allescher, HD; Daniel, EE; Fox, JE; Kostolanska, F; Rovati, LA, 1989
)
0.28
" Their respective dose-response curves had a similar maximum but the slope of the curve for AMPA was consistently steeper than that for quisqualate."( The pharmacology of quisqualate and AMPA in the cerebral cortex of the rat in vitro.
Horne, AL; Simmonds, MA, 1989
)
0.28
" Close correlation between the decrease in gall bladder volume and the dosage of CCK or the increments in plasma CCK-bioactivity was observed."( CCK receptor antagonism by loxiglumide and gall bladder contractions in response to cholecystokinin, sham feeding and ordinary feeding in man.
Bogdal, J; Konturek, JW; Konturek, SJ; Kurek, A; Oleksy, J; Rovati, L, 1989
)
0.28
" The dose-response relationship of EAA (N-methyl-D-aspartate (NMDA), kainate, quisqualate and glutamate)-induced activation revealed qualitative and quantitative differences in their pattern of action, suggesting that these agonists act at distinct receptors."( Behavioral classification of excitatory amino acid receptors in mouse spinal cord.
Raigorodsky, G; Urca, G, 1988
)
0.27
" Whereas the reduction in Ca2+i was related to the extracellular glucose concentration in a hyperbolic manner, the increasing component exhibited a sigmoidal dose-response relationship."( Nutrient secretagogues induce bimodal early changes in cytoplasmic calcium of insulin-releasing ob/ob mouse beta-cells.
Gylfe, E, 1988
)
0.27
" Proglumide and CR-1392 caused a rightward and parallel shift, respectively, in the dose-response curve of CCK8 stimulated pancreatic protein secretion in anesthetized rats, demonstrating a competitive-like mechanism of inhibition."( The anti-CCK effect of glutaramic acid derivatives in anesthetized and conscious rats.
Nagy, I; Pap, A; Takács, T; Varró, V, 1988
)
0.27
" Dose-response curves have shown more than 70% inhibition of tumor growth with a glutamine concentration of 50% and an asparagine concentration of 25%."( Amino acid requirements of a rat sarcoma as determined by a stem cell assay.
Chance, WT; Franco, RS; Martelo, OJ; Miller, TJ; Popp, MB,
)
0.13
" The log dose-response curve for depolarization was sigmoid with a mean ED(50) of 12."( Depolarizing actions of gamma-aminobutyric acid and related compounds on rat superior cervical ganglia in vitro.
Bowery, NG; Brown, DA, 1974
)
0.25
" The gln4-1 mutation is specific for Gln-tRNA synthetase and shows a dosage effect in heterozygous diploids."( Identification of a glutaminyl-tRNA synthetase mutation Saccharomyces cerevisiae.
Ludmerer, SW; Mitchell, AP, 1984
)
0.27
" Dose-response curves to CCK for amylase release shifted to the right with increase in proglumide concentration."( In vitro and in vivo effect of proglumide on cholecystokinin-stimulated amylase release in mouse pancreatic acini.
Akanuma, Y; Iwamoto, Y; Nakamura, R, 1984
)
0.27
" The dose-response curve for cAMP formation stimulated by epinephrine was shifted 1 log unit to the right in uremic muscle and adenylyl cyclase stimulation by epinephrine was shifted 1 log unit."( Skeletal muscle amino acid metabolism in chronic uremia.
Garber, AJ; Maillet, C, 1980
)
0.26
" In the case of secretagogue stimulation (1) benzotript slightly affected histamine-induced AP (15% inhibition at 5 X 10(-3) M), proglumide did not; (2) both proglumide and benzotript inhibited in a non-competitive manner acetylcholine-induced AP; (3) these isolated cells were sensitive to gastrin and the dose-response curve for the stimulant was biphasic (maximum for 1 X 10(-9) M), suggesting a desensitization mechanism."( Evidence that proglumide and benzotript antagonize secretagogue stimulation of isolated gastric parietal cells.
Bali, JP; Magous, R, 1983
)
0.27
" Administration of aspirin decreased the gastric mucosal hexosamine and induced the onset of ulcer, while administration of proglumide suppressed the gastric lesions in proportion to dosage and correspondingly prevented a decrease of the hexosamine."( The role of gastric mucosal hexosamine in aspirin-induced ulcers.
Aono, M; Moriga, M; Murakami, M; Uchino, H, 1980
)
0.26
" One of six patients with glioblastoma multiforme, whose steroid dosage has remained unchanged for the duration of therapy, has sustained functional improvement for more than 9 months."( A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer.
Cooper, MR; Figg, WD; Headlee, DJ; McCall, NA; Samid, D; Sartor, AO; Thibault, A; Tompkins, AC; Venzon, DJ; Weinberger, MS, 1994
)
0.29
" The authors conclude that EGF markedly increases the functional capacity of the small intestine in rabbits that have undergone extensive small bowel resection; this effect persists for up to 6 weeks after a small initial dosage of EGF."( Delayed effects of epidermal growth factor after extensive small bowel resection.
Diamond, J; Fonkalsrud, EW; Guo, W; Swaniker, F, 1996
)
0.29
" No pathological accumulation of free glycine or of the dipeptide was seen with any of the three dosage steps of GLY-GLN."( Safety and efficacy of increasing dosages of glycyl-glutamine for total parenteral nutrition in polytrauma patients.
Fridrich, P; Germann, P; Götzinger, P; Karner, J; Mauritz, W; Mittlböck, M; Roth, E; Weingartmann, G, 1996
)
0.29
" Combined UV, 1H NMR, and positive-ion electrospray MS detection was achieved in the continuous-flow mode using whole human urine from a subject dosed with acetaminophen."( Combined HPLC, NMR spectroscopy, and ion-trap mass spectrometry with application to the detection and characterization of xenobiotic and endogenous metabolites in human urine.
Foxall, PJ; Lindon, JC; Nicholson, JK; Shockcor, JP; Unger, SE; Wilson, ID, 1996
)
0.29
" However, the definition of indications and dose-response relationships clearly require further clinical studies."( Role of glutamine in the immune response in critical illness.
Babst, R; Gross, T; Harder, F; Heberer, M; Hörig, H; Juretic, A; Spagnoli, GC,
)
0.13
" Generalized tonic-clonic seizures observed in EP mice were inhibited by valproate, administered 1 h prior to testing, in a dose-response fashion."( Effects of valproate on amino acid and monoamine concentrations in striatum of audiogenic seizure-prone Balb/c mice.
Alexiuk, NA; Vriend, JP, 1996
)
0.29
" It is important to realise, however, that the glia-specificity of these compounds depends both on the dosage and on the model used."( Use of fluorocitrate and fluoroacetate in the study of brain metabolism.
Fonnum, F; Hassel, B; Johnsen, A, 1997
)
0.3
" At the highest dosage (40 mM) the b-wave was significantly reduced within 2 min of injection."( Inhibition of Müller cell glutamine synthetase rapidly impairs the retinal response to light.
Barnett, NL; Pow, DV; Robinson, SR, 2000
)
0.31
"Pharmacokinetic responses to oral doses of the dipeptide, L-alanyl-glutamine (Ala-Gln), were evaluated after a single, bolus load or an intermittent dosing in normal healthy subjects (n = 8) to find the optimal mode of oral administration."( The pharmacokinetic responses of humans to 20 g of alanyl-glutamine dipeptide differ with the dosing protocol but not with gastric acidity or in patients with acute Dengue fever.
Fürst, P; Klassen, P; Mazariegos, M; Solomons, NW, 2000
)
0.31
" Further prospective studies should be performed to define the optimal dosage of sodium phenylbutyrate and the requirements for protein diet at different ages."( Long-term treatment with sodium phenylbutyrate in ornithine transcarbamylase-deficient patients.
Burlina, AB; Korall, H; Ogier, H; Trefz, FK, 2001
)
0.31
" Using L-threonine and L-glutamine as representative amino acids, this study was undertaken to estimate apparent simple diffusion of L-amino acids and to establish the effective dosage of HgCl2 for completely blocking carrier-mediated L-amino acid transport in porcine jejunal enterocyte brush border membrane vesicles."( Estimation of apparent L-amino acid diffusion in porcine jejunal enterocyte brush border membrane vesicles.
Asem, EK; Fan, MZ, 2001
)
0.31
" The increased values of aluminum were significantly related to the dosage of aluminum."( [Effects of aluminum on amino acid neurotransmitters in hippocampus of rats].
Jia, Y; Wang, Y; Zhong, C, 2001
)
0.31
" Nutritional status of patients cannot be improved by the mode and dosage of parenteral glutamine used in our study."( [Parenteral glutamine does not improve the nutritional status in patients during high-dose chemotherapy and autologous peripheral stem cell transplantation].
Andĕl, M; Benes, P; Chocenská, E; Gregora, E; Klepetár, J; Kozák, T; Pat'orková, M; Procházka, B; Pytlík, R, 2002
)
0.31
" The median duration of treatment was 6 months and the average dosage of antineoplaston A10 was 11."( Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report.
Axler, ML; Bestak, M; Burzynski, SR; Janicki, TJ; Jurida, GF; Khan, MI; Lewy, RI; Paszkowiak, JK; Szymkowski, BG; Weaver, RA, 2003
)
0.32
"The capacity-limited conversion of PAA to PAG has important implications for the dosing of PAA, and the pharmacokinetic model described here may be useful for individualizing the infusion rate of the drug in future clinical trials."( Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer.
Adamson, P; Aiken, A; Balis, F; Berg, S; Blaney, SM; Jakacki, R; Klenke, R; Murry, DJ; Packer, R; Serabe, BM; Thompson, P, 2003
)
0.32
" The CG group received the same creatine dosage scheme as the CM group plus 4 g glutamine."( The effects of 8 weeks of creatine monohydrate and glutamine supplementation on body composition and performance measures.
Haff, EE; Haff, GG; Justice, B; Kilgore, JL; Lehmkuhl, M; Malone, M; Pistilli, E; Trone, G; Vinci, D, 2003
)
0.32
"5 g/kg were supplied orally for 14 days in Gln group, and the same dosage of placebo were given for 14 days in B group."( Effects of enteral supplementation with glutamine granules on intestinal mucosal barrier function in severe burned patients.
Peng, X; Wang, P; Wang, S; Yan, H; You, Z, 2004
)
0.32
"2 U kg(-1) d(-1) in addition to glutamine in same dosage beginning on the 7 PBD for 7 days."( [The influence of combined supplementation of glutamine and recombinant human growth hormone on the protein metabolism in severely burned patients].
Cao, GZ; Hong, BS; Lin, C; Lu, CJ; Xu, JJ; Zhang, P, 2004
)
0.32
"The optimal dosage of ornithine alpha-ketoglutarate (OKG) for repleting tissue glutamine (Gln) concentrations and maintaining N homeostasis after injury is unknown."( Dose dependency of the effect of ornithine alpha-ketoglutarate on tissue glutamine concentrations and hypercatabolic response in endotoxaemic rats.
Coudray-Lucas, C; Cynober, L; Jardel, A; Pernet, P; Schneid, C, 2004
)
0.32
" The dose-response effect of "Deglutam" on the studied enzymes depended on the mode of preparation administration."( [The regulatory action of dipeptide "Deglutam" on the glutamine metabolized enzymes in the carcinosarcoma SM-1 cells].
, 2005
)
0.33
" The average dosage of A10 was 10."( Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1.
Burzynski, SR; Dolgopolov, V; Janicki, T; Jurida, G; Khan, M; Szymkowski, B; Weaver, RA, 2005
)
0.33
" Each time point of LPS and Gln as well as control rats were anaesthetized at each time point with 1% chloral hydrate injected intraperitoneally at the dosage of 1 ml/kg."( [Effects of glutamine on alpha-sarcomeric actin and its mRNA expression of myocardium in rats with endotoxemia].
Gao, H; Pan, JK; Sun, M; Wang, H; Zhou, Z, 2005
)
0.33
" On each time point, rats of LPS and Gln groups as well as control group were anesthetized with 1% chloral hydrate injected intraperitoneally at a dosage of 1 ml/kg."( [Effects of glutamine on matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-3 expressions in myocardium of rats with sepsis].
Gao, H; Pan, JK; Sun, M; Wang, H; Yu, XY, 2006
)
0.33
" There are currently insufficient data to enable useful recommendations on the optimal route, timing, duration and dosage of each nutrient."( Pharmaconutrition: a new emerging paradigm.
Heyland, DK; Jones, NE, 2008
)
0.35
" Acidosis shifted the dose-response curve for suppression of proteolysis by insulin to the right, confirming that acid increases proteolysis by inducing insulin resistance."( Inhibition of SNAT2 by metabolic acidosis enhances proteolysis in skeletal muscle.
Amin, A; Bevington, A; Brown, J; Clapp, E; Evans, K; Herbert, TP; Nasim, Z; Yang, B, 2008
)
0.35
"This schedule and dosage of glutamine may be beneficial in the prevention of ARIE and weight loss in lung cancer patients undergoing thoracic irradiation."( Prevention of acute radiation-induced esophagitis with glutamine in non-small cell lung cancer patients treated with radiotherapy: evaluation of clinical and dosimetric parameters.
Onal, C; Topkan, E; Yavuz, AA; Yavuz, MN, 2009
)
0.35
" There is clinical heterogeneity in terms of routes of administration, dosing schedules, chemotherapy regimens and diseases."( Hot topics in parenteral nutrition. A review of the use of glutamine supplementation in the nutritional support of patients undergoing bone-marrow transplantation and traditional cancer therapy.
Crowther, M, 2009
)
0.35
"The current literature demonstrates that there are currently insufficient data to enable confident recommendations on the optimal route, timing, duration and dosage of each of these nutritional supplements."( Selenium and glutamine supplements: where are we heading? A critical care perspective.
Andrews, PJ, 2010
)
0.36
" Blood ammonia and blood and urine metabolites were compared after 7 days (steady state) of TID dosing on either drug, both dosed to deliver the same amount of phenylbutyric acid (PBA)."( Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control.
Beliveau, M; Berry, SA; Diaz, GA; Dickinson, K; Gargosky, S; Lee, B; Marier, JF; Martinez, A; Mauney, J; Mian, A; Mokhtarani, M; Rhead, W; Scharschmidt, BF; Shchelochkov, O, 2010
)
0.36
" Twenty-four healthy adults underwent single-dose administration of GPB and NaPBA and eight healthy adults and 24 cirrhotic subjects underwent single-day and multiple-day dosing of GPB, with metabolites measured in blood and urine."( Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis.
Dickinson, K; Gargosky, S; Lowe, ME; Martinez, A; McGuire, BM; Mokhtarani, M; Monteleone, J; Scharschmidt, BF; Syplyviy, VA; Xiao, X; Zupanets, IA, 2010
)
0.36
" The incidence of this side effect is related to the dosage and can be as high as 75%."( Oral glutamine attenuates cyclophosphamide-induced oxidative stress in the bladder but does not prevent hemorrhagic cystitis in rats.
Abraham, P; Isaac, B; Natarajan, K; Ramamoorthy, H, 2011
)
0.37
" Minimum therapeutic and maximum tolerated dosages of creatine are not yet known, nor is it known what systemic plasma concentrations result from specific dosage regimens."( A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis.
Atassi, N; Bombardier, J; Cudkowicz, M; Dibernardo, A; Eckenrode, J; Greenblatt, DJ; Pulley, D; Ratai, EM; Wallace, S; Zhao, Y, 2010
)
0.36
" Parenteral glutamine appears to confer benefit in selected patients; however, additional data to define optimal glutamine dosing and the patient subgroups who may most benefit from this amino acid are needed."( Amino acid composition in parenteral nutrition: what is the evidence?
Hebbar, G; Yarandi, SS; Zhao, VM; Ziegler, TR, 2011
)
0.37
"Despite routine use of parenteral nutrition, surprisingly little clinical efficacy data are available to guide total or specific amino acid dosing in adult and pediatric patients requiring this therapy."( Amino acid composition in parenteral nutrition: what is the evidence?
Hebbar, G; Yarandi, SS; Zhao, VM; Ziegler, TR, 2011
)
0.37
" The study consisted of three experiments: The first was a dose-finding study of four different dosing regimens of magnesium sulfate (MgSO4) in healthy rats."( Hypermagnesemia does not prevent intracranial hypertension and aggravates cerebral hyperperfusion in a rat model of acute hyperammonemia.
Bernal, W; Bjerring, PN; Eefsen, M; Larsen, FS; Wendon, J, 2011
)
0.37
" Macroscopic and microscopic effects occurred at low frequency but were not associated with a dose-response relationship."( Oral subchronic and genotoxicity studies conducted with the amino acid, L-glutamine.
Bursey, RG; Magnuson, BA; Nakagawa, K; Wong, AW, 2011
)
0.37
" This review will focus on mechanism of action, adverse effects and drug interactions reported in the literature, and appropriate dosing and outcomes data for specific nutritional supplements in various critically ill adult populations."( Nutritional supplements in critical illness.
Bullington, WM; Cooper, TB; Hayes, GL; McKinzie, BP; Pilch, NA,
)
0.13
"This pilot study showed that pharmacologically dosed oral GLN therapy prior to cardiac surgery was safe, well tolerated, and feasible."( Pharmacologically dosed oral glutamine reduces myocardial injury in patients undergoing cardiac surgery: a randomized pilot feasibility trial.
Dauber, I; Hamiel, C; Queensland, K; Rooyackers, O; Sufit, A; Weitzel, LB; Wischmeyer, PE, 2012
)
0.38
"We have analyzed pharmacokinetic data for glycerol phenylbutyrate (also GT4P or HPN-100) and sodium phenylbutyrate with respect to possible dosing biomarkers in patients with urea cycle disorders (UCD)."( Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders.
Bart, S; Bartholomew, D; Bartley, J; Berquist, W; Berry, SA; Cederbaum, S; Coakley, DF; Diaz, GA; Dickinson, K; Dorrani, N; Feigenbaum, A; Gallagher, R; Harding, CO; Korson, MS; Kronn, D; Lee, B; Lemons, C; Lichter-Konecki, U; Longo, N; McCandless, SE; Merritt, JL; Mokhtarani, M; Moors, TL; Rhead, W; Scharschmidt, BF; Smith, W; Sreenath-Nagamani, S; Summar, M; Vockley, J; Zori, R, 2012
)
0.38
" A dose-response analysis of the most active compounds gave IC(50) values in the range of 3-30μM."( Inactivation of the glutamine/amino acid transporter ASCT2 by 1,2,3-dithiazoles: proteoliposomes as a tool to gain insights in the molecular mechanism of action and of antitumor activity.
Carotti, A; Catto, M; Indiveri, C; Introcaso, A; Koutentis, PA; Koyioni, M; Michaelidou, SS; Nicolotti, O; Oppedisano, F; Pochini, L, 2012
)
0.38
"Forty-eight Wistar rats were divided into 4 groups randomly:control group,low dosage group, moderate dosage group and high dosage group."( [Effect of subchronic realgar exposure on Glu and Gln in infant rat brain].
Chang, B; Huo, TG; Jiang, H; Li, WK; Sun, GF; Yang, HL; Zhang, YH, 2012
)
0.38
"The levels of MMA and DMA in brain increased as the dosage of realgar increased, while the second methylation index declined."( [Effect of subchronic realgar exposure on Glu and Gln in infant rat brain].
Chang, B; Huo, TG; Jiang, H; Li, WK; Sun, GF; Yang, HL; Zhang, YH, 2012
)
0.38
" Dose simulations demonstrated similar PAA exposure following mole-equivalent PBA dosing of both drugs and greater PAA exposure in younger patients based on BSA."( Population pharmacokinetic modeling and dosing simulations of nitrogen-scavenging compounds: disposition of glycerol phenylbutyrate and sodium phenylbutyrate in adult and pediatric patients with urea cycle disorders.
Berry, SA; Coakley, D; Diaz, GA; Dickinson, K; Lee, B; Lemons, C; Lichter-Konecki, U; Mokhtarani, M; Monteleone, JP; Rhead, W; Scharschmidt, BF, 2013
)
0.39
" The plasma PAA:PAGN ratio is a functional measure of the rate of PAA metabolism and represents a useful dosing biomarker."( Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio.
Bartley, J; Berquist, W; Berry, SA; Brown, RS; Coakley, D; Diaz, GA; Dickinson, K; Feigenbaum, A; Gallagher, R; Ghabril, M; Harding, C; Lee, B; Lemons, C; Lichter-Konecki, U; Longo, N; Mantry, P; McCandless, SE; Milikien, DA; Mokhtarani, M; Moors, T; Nagamani, SC; Norris, C; Rhead, W; Rockey, DC; Scharschmidt, BF; Schulze, A; Smith, W; Vierling, JM, 2013
)
0.39
" A significant part of the probiotic was dosed orally to reduce the variability of intake of the probiotic."( Effects of age and controlled oral dosing of Enterococcus faecium on epithelial properties in the piglet small intestine.
Aschenbach, JR; Dillenseger, A; Lodemann, U; Martens, H, 2013
)
0.39
"UCD patients (n=26) ages 2months through 17years were treated with GPB and sodium phenylbutyrate (NaPBA) in two short-term, open-label crossover studies, which compared 24-hour ammonia exposure (AUC0-24) and glutamine levels during equivalent steady-state dosing of GPB and sodium phenylbutyrate (NaPBA)."( Glycerol phenylbutyrate treatment in children with urea cycle disorders: pooled analysis of short and long-term ammonia control and outcomes.
Berry, SA; Coakley, DF; Diaz, GA; Lee, B; Lemons, C; Lichter-Konecki, U; McCandless, SE; Mokhtarani, M; Nagamani, SC; Rhead, W; Scharschmidt, BF; Smith, W, 2014
)
0.4
" Mean ammonia levels remained within the normal range during 12months of GPB dosing and, when compared with the 12months preceding enrollment, a smaller percentage of patients (24."( Glycerol phenylbutyrate treatment in children with urea cycle disorders: pooled analysis of short and long-term ammonia control and outcomes.
Berry, SA; Coakley, DF; Diaz, GA; Lee, B; Lemons, C; Lichter-Konecki, U; McCandless, SE; Mokhtarani, M; Nagamani, SC; Rhead, W; Scharschmidt, BF; Smith, W, 2014
)
0.4
"Dosing with GPB was associated with 24-hour ammonia exposure that was non-inferior to that during dosing with NaPBA in individual studies and significantly lower in the pooled analysis."( Glycerol phenylbutyrate treatment in children with urea cycle disorders: pooled analysis of short and long-term ammonia control and outcomes.
Berry, SA; Coakley, DF; Diaz, GA; Lee, B; Lemons, C; Lichter-Konecki, U; McCandless, SE; Mokhtarani, M; Nagamani, SC; Rhead, W; Scharschmidt, BF; Smith, W, 2014
)
0.4
" We conclude that endogenous N/OFQ functionally opposes DOP transmission in substantia nigra reticulata and that NOP receptor antagonists might be used in combination with DOP receptor agonists to reduce their dosage while maintaining their full therapeutic efficacy."( Stimulation of δ opioid receptor and blockade of nociceptin/orphanin FQ receptor synergistically attenuate parkinsonism.
Ledonne, A; Mabrouk, OS; Mercuri, N; Morari, M; Viaro, R; Volta, M, 2014
)
0.4
" Future glutamine dose-response studies are warranted in these areas."( Effect of glutamine supplementation on cardiovascular risk factors in patients with type 2 diabetes.
Heshmat, R; Hosseini, S; Larijani, B; Mansour, A; Mohajeri-Tehrani, MR; Qorbani, M, 2015
)
0.42
" We show that for the rat chronically dosed with dexamethasone (an artificial glucocorticoid which induces a catabolic state) the model can be used to explain empirically observed facts such as the linear decline in intramuscular Gln and the drop in plasma glutamine."( The role of skeletal muscle in liver glutathione metabolism during acetaminophen overdose.
Bilinsky, LM; Nijhout, HF; Reed, MC, 2015
)
0.42
" Once conventional liposomes are readily recognized and captured by immune system cells, the encapsulation of glutamine into those nanosystems could be an alternative to reduce glutamine dosage and target then to neutrophils."( Glutamine-Loaded Liposomes: Preliminary Investigation, Characterization, and Evaluation of Neutrophil Viability.
Almeida, FF; Cadena, PG; Costa, LC; Lagranha, CJ; Lira-Nogueira, MC; Santos-Magalhães, NS; Souza, BN, 2016
)
0.43
"Single oral dosing of encapsulated glutamine did not provoke consistent increases in GLP-1 and insulin secretion and was not associated with beneficial metabolic effects in healthy volunteers or patients with type 2 diabetes."( The effect of encapsulated glutamine on gut peptide secretion in human volunteers.
Gribble, F; Lewis, HB; Meek, CL; Park, A; Reimann, F; Vergese, B, 2016
)
0.43
" Both biochemical and morphological studies clearly revealed that chrysin protects against cell injury induced by ammonia intoxication in a dose-response manner with respect to endogenous antioxidants and hypoammonemic effects."( Chrysin, a flavonoid attenuates histological changes of hyperammonemic rats: A dose dependent study.
Ramakrishnan, A; Renuka, M; Vijayakumar, N, 2016
)
0.43
" A dose-response relationship was observed for all effects."( Ammonium accumulation is a primary effect of 2-methylcitrate exposure in an in vitro model for brain damage in methylmalonic aciduria.
Ballhausen, D; Braissant, O; Cudré-Cung, HP; do Vale-Pereira, S; Henry, H; Ivanisevic, J; Remacle, N; Tavel, D; Zavadakova, P, 2016
)
0.43
" They were given glutamine three times daily at a dosage of 9 g/day."( Effects of two different glutamine-containing enteral supplements on stool frequency and density in elderly patients recovering from acute critical illness.
Fushimi, N; Hachiya, H; Ito, S; Mori, A; Ohashi, N; Shibuya, T; Yamada, M, 2017
)
0.46
"To examine the dose-response effects of acute glutamine supplementation on markers of gastrointestinal (GI) permeability, damage and, secondary, subjective symptoms of GI discomfort in response to running in the heat."( Glutamine supplementation reduces markers of intestinal permeability during running in the heat in a dose-dependent manner.
Close, GL; Doran, DA; Fleming, SC; Highton, J; Hutson, M; Morton, JP; Pugh, JN; Sage, S, 2017
)
0.46
" Evaluation of past studies suggests that the major impediments to successful clinical use included unacceptable gastrointestinal (GI) toxicities, inappropriate dosing schedules for a metabolic inhibitor, and lack of targeted patient selection."( We're Not "DON" Yet: Optimal Dosing and Prodrug Delivery of
Lemberg, KM; Rais, R; Slusher, BS; Vornov, JJ, 2018
)
0.48
" Covariate analyses indicated that age did not influence the PK parameters, with body surface area (BSA) being the most significant covariate, reinforcing current BSA based dosing recommendations as seen in older patients."( Pharmacokinetics of glycerol phenylbutyrate in pediatric patients 2 months to 2 years of age with urea cycle disorders.
Berry, SA; Diaz, GA; Dong, M; Ficicioglu, C; Harding, CO; Holt, RJ; Lichter-Konecki, U; Longo, N; McCandless, SE; Perdok, R; Robinson, B; Smith, WE; Vinks, AA; Vockley, J; Zori, R, 2018
)
0.48
" Sorafenib dosage was 400 mg/day for both groups."( β-Hydroxy-β-methyl Butyrate/L-Arginine/L-Glutamine Supplementation for Preventing Hand-Foot Skin Reaction in Sorafenib for Advanced Hepatocellular Carcinoma.
Hatanaka, T; Horiguchi, S; Hoshino, T; Ishihara, H; Kakizaki, S; Kudo, T; Murakami, T; Naganuma, A; Ogawa, Y; Ohno, N; Sato, K; Suzuki, Y; Takagi, H; Uehara, D,
)
0.13
" Moreover, the KD-R diet facilitated DON delivery to the brain and allowed a lower dosage to achieve therapeutic effect."( Therapeutic benefit of combining calorie-restricted ketogenic diet and glutamine targeting in late-stage experimental glioblastoma.
Arismendi-Morillo, G; Augur, ZM; Bronson, RT; Chinopoulos, C; Domin, MA; Greenwood, B; Hill, C; Kiebish, MA; Kondakci, G; Li, M; Mukherjee, P; Narain, NR; Seyfried, TN, 2019
)
0.51
" Caloric dosing is ideally guided by indirect calorimetry, and endogenous energy production should be considered."( Nutrition in Sepsis: A Bench-to-Bedside Review.
De Waele, E; Malbrain, MLNG; Spapen, H, 2020
)
0.56
"Determine the minimum dosage of alanyl-glutamine (Ala-Gln) required to improve gut integrity and growth in children at risk of environmental enteropathy (EE)."( Intervention and Mechanisms of Alanyl-glutamine for Inflammation, Nutrition, and Enteropathy: A Randomized Controlled Trial.
Filho, JQ; Guedes, MM; Guerrant, RL; Havt, A; Junior, FS; Lanzarini Lopes, GML; Lima, AAM; Lima, NL; Maier, EA; Mayneris-Perxachs, J; Moore, SR; Perry, M; Quetz, JS; Quinn, LA; Ramprasad, C; Soares, AM; Swann, J, 2020
)
0.56
"This was a double-blinded randomized placebo-controlled dose-response trial."( Intervention and Mechanisms of Alanyl-glutamine for Inflammation, Nutrition, and Enteropathy: A Randomized Controlled Trial.
Filho, JQ; Guedes, MM; Guerrant, RL; Havt, A; Junior, FS; Lanzarini Lopes, GML; Lima, AAM; Lima, NL; Maier, EA; Mayneris-Perxachs, J; Moore, SR; Perry, M; Quetz, JS; Quinn, LA; Ramprasad, C; Soares, AM; Swann, J, 2020
)
0.56
" GDH activity, GDH relative mRNA and protein expression, GS activity, GS relative mRNA and protein expression increased significantly and showed a pronounced time and dosage interaction in the liver."( The razor clam Sinonovacula constricta uses the strategy of conversion of toxic ammonia to glutamine in response to high environmental ammonia exposure.
Dong, Y; Lin, Z; Sun, G; Yao, H; Zhang, H, 2020
)
0.56
" Ornithine phenylacetate, an intravenous dosage form of the L-ornithine salt of phenylacetate, is under development for hepatic encephalopathy."( Exposures of Phenylacetic Acid and Phenylacetylglutamine Across Different Subpopulations and Correlation with Adverse Events.
Mak, C; Poola, N; Tseng, J; Vilchez, RA; Wang, X, 2021
)
0.62
"This analysis summarized the pharmacokinetics and safety of ornithine phenylacetate to support the dosing strategy and to assist with the monitoring and management of neurologic adverse events in a global clinical development program."( Exposures of Phenylacetic Acid and Phenylacetylglutamine Across Different Subpopulations and Correlation with Adverse Events.
Mak, C; Poola, N; Tseng, J; Vilchez, RA; Wang, X, 2021
)
0.62
" Also, glutathione serum dosage was higher in G2-Dip."( Oral glutamine dipeptide or oral glutamine free amino acid reduces burned injury progression in rats.
Beldi, VFM; Evora, PRB; Farina Junior, JA; Jordão, AA; Moriguti, EKU; Rosique, MJ; Tirapelli, DPC; Tirapelli, LF, 2021
)
0.62
" However, high dosage of chemotherapy is associated with drug resistance and side effects."( Inhibition of lncRNA NEAT1 sensitizes medulloblastoma cells to cisplatin through modulating the miR-23a-3p-glutaminase (GLS) axis.
Ge, J; Wang, B; Xu, J; Zhao, S, 2022
)
0.72
" Single strain probiotic strains showed some positive findings, but the results are likely strain, dosage and duration specific."( A systematic review: Role of dietary supplements on markers of exercise-associated gut damage and permeability.
Chantler, S; Davison, G; Griffiths, A; Holliday, A; Jones, B; Matu, J, 2022
)
0.72
" The average dose was 170 mL of AG or control based on a dosing scheme of 1 g/kg bodyweight."( A randomized double-blind controlled proof-of-concept study of alanyl-glutamine for reduction of post-myomectomy adhesions.
Chizen, DR; De Wilde, RL; Gargiulo, AR; Lim, HJ; Pierson, RA; Rislund, DC; Robertson, LM; Tulandi, T; Velygodskiy, A, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (8)

RoleDescription
EC 1.14.13.39 (nitric oxide synthase) inhibitorAn EC 1.14.13.* (oxidoreductase acting on paired donors, incorporating 1 atom of oxygen, with NADH or NADPH as one donor) inhibitor that interferes with the action of nitric oxide synthase (EC 1.14.13.39).
nutraceuticalA product in capsule, tablet or liquid form that provide essential nutrients, such as a vitamin, an essential mineral, a protein, an herb, or similar nutritional substance.
micronutrientAny nutrient required in small quantities by organisms throughout their life in order to orchestrate a range of physiological functions.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
glutamineAn alpha-amino acid that consists of butyric acid bearing an amino substituent at position 2 and a carbamoyl substituent at position 4.
L-alpha-amino acidAny alpha-amino acid having L-configuration at the alpha-carbon.
glutamine family amino acidAn L-alpha-amino acid which is L-glutamic acid or any of the essential amino acids biosynthesised from it (glutamine, proline and arginine). A closed class.
proteinogenic amino acidAny of the 23 alpha-amino acids that are precursors to proteins, and are incorporated into proteins during translation. The group includes the 20 amino acids encoded by the nuclear genes of eukaryotes together with selenocysteine, pyrrolysine, and N-formylmethionine. Apart from glycine, which is non-chiral, all have L configuration.
amino acid zwitterionThe zwitterionic form of an amino acid having a negatively charged carboxyl group and a positively charged amino group.
polar amino acid zwitterion
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (126)

PathwayProteinsCompounds
Nicotinate and Nicotinamide Metabolism1434
Pyrimidine Metabolism2353
Urea Cycle1325
Aspartate Metabolism1430
Glutamate Metabolism2244
Purine Metabolism3766
Amino Sugar Metabolism1731
Ammonia Recycling1227
Phenylacetate Metabolism38
4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency2244
Homocarnosinosis2244
Hyperinsulinism-Hyperammonemia Syndrome2244
Adenosine Deaminase Deficiency3766
Adenylosuccinate Lyase Deficiency3766
Gout or Kelley-Seegmiller Syndrome3766
Lesch-Nyhan Syndrome (LNS)3766
Molybdenum Cofactor Deficiency3766
Xanthine Dehydrogenase Deficiency (Xanthinuria)3766
Purine Nucleoside Phosphorylase Deficiency3766
AICA-Ribosiduria3766
Canavan Disease1430
Hypoacetylaspartia1430
Sialuria or French Type Sialuria1731
Salla Disease/Infantile Sialic Acid Storage Disease1731
Argininemia1325
Argininosuccinic Aciduria1325
Citrullinemia Type I1325
Ornithine Transcarbamylase Deficiency (OTC Deficiency)1325
beta-Ureidopropionase Deficiency2353
UMP Synthase Deficiency (Orotic Aciduria)2353
Dihydropyrimidinase Deficiency2353
MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy)2353
Carbamoyl Phosphate Synthetase Deficiency1325
2-Hydroxyglutric Aciduria (D and L Form)2244
Tay-Sachs Disease1731
Azathioprine Action Pathway4782
Mercaptopurine Action Pathway4780
Thioguanine Action Pathway4781
Xanthinuria Type I3766
Xanthinuria Type II3766
G(M2)-Gangliosidosis: Variant B, Tay-Sachs Disease1731
Adenine Phosphoribosyltransferase Deficiency (APRT)3766
Mitochondrial DNA Depletion Syndrome-33766
Myoadenylate Deaminase Deficiency3766
Succinic Semialdehyde Dehydrogenase Deficiency2244
Mercaptopurine Metabolism Pathway1524
Warburg Effect4652
Nitrogen Metabolism2622
D-Glutamine and D-Glutamate Metabolism1517
L-Glutamate Metabolism2420
Arginine Metabolism2848
tRNA Charging5227
tRNA Charging 22225
Histidine Biosynthesis821
Asparagine Biosynthesis612
NAD Biosynthesis520
NAD Salvage620
Lipopolysaccharide Biosynthesis4153
Amino Sugar and Nucleotide Sugar Metabolism I1733
Peptidoglycan Biosynthesis I3036
Folate Biosynthesis1126
Purine Nucleotides De Novo Biosynthesis2945
Secondary Metabolites: Histidine Biosynthesis820
Lipopolysaccharide Biosynthesis II4053
Tryptophan Metabolism II623
Thiamin Diphosphate Biosynthesis1027
Purine Nucleotides De Novo Biosynthesis 22945
Lipopolysaccharide Biosynthesis III3352
Peptidoglycan Biosynthesis II3037
O-Antigen Building Blocks Biosynthesis922
Asparagine Metabolism412
The Oncogenic Action of 2-Hydroxyglutarate2734
Glutaminolysis and Cancer3536
Amino Sugar and Nucleotide Sugar Metabolism2229
Tetrahydrofolate Biosynthesis829
NAD Metabolism1435
The Oncogenic Action of L-2-Hydroxyglutarate in Hydroxyglutaric aciduria2835
The Oncogenic Action of D-2-Hydroxyglutarate in Hydroxyglutaric aciduria2936
Glutamine Metabolism2225
Glutamic Acid Metabolism1317
Nicotinate and Nicotinamide metabolism ( Nicotinate and Nicotinamide metabolism )2225
Mitochondrial DNA Depletion Syndrome3566
Alanine,Aspartic acid and Asparagine metabolism ( Alanine,Aspartic acid and Asparagine metabolism )2237
Aminosugars metabolism ( Aminosugars metabolism )1529
L-Glutamine + D-Fructose 6-phosphate = L-Glutamic acid + D-Glucosamine 6-phosphate ( Fructose and Mannose metabolism )24
ATP + L-Glutamic acid + NH3 = ADP + L-Glutamine + Orthophosphate ( Glutamic acid and Glutamine metabolism )16
Glutamic acid and Glutamine metabolism ( Glutamic acid and Glutamine metabolism )1926
L-Glutamine + H2O = L-Glutamic acid + NH3 ( Glutamic acid and Glutamine metabolism )24
Purine nucleotides and Nucleosides metabolism ( Purine nucleotides and Nucleosides metabolism )10577
Succinate Signalling67
Chitin Biosynthesis921
Protein Synthesis: Glutamine804
The impact of Nsp14 on metabolism (COVID-19 Disease Map)084
Oxidative stress and redox pathway019
mRNA, protein, and metabolite inducation pathway by cyclosporin A213
Amino acid metabolism in triple-negative breast cancer cells016
Metabolic pathways of fibroblasts1718
Metabolic Epileptic Disorders2589
NAD biosynthesis II (from tryptophan)024
pyrimidine nucleotide metabolism (phosphotransfer and nucleotide modification)012
uridine-5'-phosphate biosynthesis018
pyrimidine ribonucleotides de novo biosynthesis022
purine nucleotide metabolism (phosphotransfer and nucleotide modification)023
glutamine biosynthesis II07
UDP-N-acetylglucosamine biosynthesis012
tRNA charging pathway023
arginine biosynthesis I027
purine nucleotides de novo biosynthesis I039
superpathway of histidine, purine, and pyrimidine biosynthesis064
peptidoglycan and lipid A precursor biosynthesis034
purine nucleotides de novo biosynthesis II033
tetrahydrofolate biosynthesis I028
pyridine nucleotide cycling017
NAD biosynthesis I from aspartate020
NAD salvage pathway I017
AtMetExpress overview0109
Neurotransmitter release cycle021
SREBP signaling03
NAD biosynthesis II from tryptophan024
Sterol regulatory element-binding proteins (SREBP) signaling13
Synaptic vesicle pathway07
Metabolism overview078
Biochemical pathways: part I0466
Amino acid metabolism094
Pyrimidine metabolism038
Ferroptosis133
Amino acid conjugation05

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin reductaseRattus norvegicus (Norway rat)Potency1.77830.100020.879379.4328AID588453
15-lipoxygenase, partialHomo sapiens (human)Potency39.81070.012610.691788.5700AID887
GLS proteinHomo sapiens (human)Potency5.62340.35487.935539.8107AID624146
arylsulfatase AHomo sapiens (human)Potency5.35821.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency20.81140.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.00280.540617.639296.1227AID2364; AID2528
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency84.921423.934123.934123.9341AID1967
flap endonuclease 1Homo sapiens (human)Potency4.74440.133725.412989.1251AID588795
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency14.12540.010323.856763.0957AID2662
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.15100.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Glutamine Binding ProteinEscherichia coliKd0.50000.50000.50000.5000AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 1Homo sapiens (human)KA100.00000.02001.72197.4000AID1397319
Carbonic anhydrase 2Homo sapiens (human)KA50.00000.01101.42737.8000AID1397320
Carbonic anhydrase-like protein, putativeTrypanosoma cruzi strain CL BrenerKA2.85000.14002.80507.5400AID1397322
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (35)

Processvia Protein(s)Taxonomy
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
L-cystine transportNeutral amino acid transporter AHomo sapiens (human)
amino acid transportNeutral amino acid transporter AHomo sapiens (human)
glutamine transportNeutral amino acid transporter AHomo sapiens (human)
L-alanine transportNeutral amino acid transporter AHomo sapiens (human)
L-cystine transportNeutral amino acid transporter AHomo sapiens (human)
proline transportNeutral amino acid transporter AHomo sapiens (human)
L-serine transportNeutral amino acid transporter AHomo sapiens (human)
threonine transportNeutral amino acid transporter AHomo sapiens (human)
hydroxyproline transportNeutral amino acid transporter AHomo sapiens (human)
synaptic transmission, glutamatergicNeutral amino acid transporter AHomo sapiens (human)
proline transmembrane transportNeutral amino acid transporter AHomo sapiens (human)
cognitionNeutral amino acid transporter AHomo sapiens (human)
L-aspartate import across plasma membraneNeutral amino acid transporter AHomo sapiens (human)
transport across blood-brain barrierNeutral amino acid transporter AHomo sapiens (human)
chloride transmembrane transportNeutral amino acid transporter AHomo sapiens (human)
L-serine import across plasma membraneNeutral amino acid transporter AHomo sapiens (human)
L-alanine import across plasma membraneNeutral amino acid transporter AHomo sapiens (human)
L-glutamate transmembrane transportNeutral amino acid transporter AHomo sapiens (human)
amino acid transportNeutral amino acid transporter B(0)Homo sapiens (human)
glutamine transportNeutral amino acid transporter B(0)Homo sapiens (human)
glutamine secretionNeutral amino acid transporter B(0)Homo sapiens (human)
neutral amino acid transportNeutral amino acid transporter B(0)Homo sapiens (human)
L-serine transportNeutral amino acid transporter B(0)Homo sapiens (human)
erythrocyte differentiationNeutral amino acid transporter B(0)Homo sapiens (human)
symbiont entry into host cellNeutral amino acid transporter B(0)Homo sapiens (human)
protein homotrimerizationNeutral amino acid transporter B(0)Homo sapiens (human)
L-aspartate import across plasma membraneNeutral amino acid transporter B(0)Homo sapiens (human)
transport across blood-brain barrierNeutral amino acid transporter B(0)Homo sapiens (human)
L-glutamine import across plasma membraneNeutral amino acid transporter B(0)Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
L-cystine transmembrane transporter activityNeutral amino acid transporter AHomo sapiens (human)
chloride channel activityNeutral amino acid transporter AHomo sapiens (human)
amino acid transmembrane transporter activityNeutral amino acid transporter AHomo sapiens (human)
L-alanine transmembrane transporter activityNeutral amino acid transporter AHomo sapiens (human)
L-aspartate transmembrane transporter activityNeutral amino acid transporter AHomo sapiens (human)
L-cystine transmembrane transporter activityNeutral amino acid transporter AHomo sapiens (human)
L-glutamine transmembrane transporter activityNeutral amino acid transporter AHomo sapiens (human)
L-proline transmembrane transporter activityNeutral amino acid transporter AHomo sapiens (human)
L-serine transmembrane transporter activityNeutral amino acid transporter AHomo sapiens (human)
L-threonine transmembrane transporter activityNeutral amino acid transporter AHomo sapiens (human)
symporter activityNeutral amino acid transporter AHomo sapiens (human)
L-hydroxyproline transmembrane transporter activityNeutral amino acid transporter AHomo sapiens (human)
virus receptor activityNeutral amino acid transporter B(0)Homo sapiens (human)
protein bindingNeutral amino acid transporter B(0)Homo sapiens (human)
amino acid transmembrane transporter activityNeutral amino acid transporter B(0)Homo sapiens (human)
L-aspartate transmembrane transporter activityNeutral amino acid transporter B(0)Homo sapiens (human)
L-glutamine transmembrane transporter activityNeutral amino acid transporter B(0)Homo sapiens (human)
L-serine transmembrane transporter activityNeutral amino acid transporter B(0)Homo sapiens (human)
symporter activityNeutral amino acid transporter B(0)Homo sapiens (human)
antiporter activityNeutral amino acid transporter B(0)Homo sapiens (human)
ligand-gated channel activityNeutral amino acid transporter B(0)Homo sapiens (human)
signaling receptor activityNeutral amino acid transporter B(0)Homo sapiens (human)
metal ion bindingNeutral amino acid transporter B(0)Homo sapiens (human)
neutral L-amino acid transmembrane transporter activityNeutral amino acid transporter B(0)Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
plasma membraneNeutral amino acid transporter AHomo sapiens (human)
centrosomeNeutral amino acid transporter AHomo sapiens (human)
intermediate filamentNeutral amino acid transporter AHomo sapiens (human)
plasma membraneNeutral amino acid transporter AHomo sapiens (human)
cell surfaceNeutral amino acid transporter AHomo sapiens (human)
membraneNeutral amino acid transporter AHomo sapiens (human)
melanosomeNeutral amino acid transporter AHomo sapiens (human)
synapseNeutral amino acid transporter AHomo sapiens (human)
extracellular exosomeNeutral amino acid transporter AHomo sapiens (human)
plasma membraneNeutral amino acid transporter B(0)Homo sapiens (human)
basal plasma membraneNeutral amino acid transporter B(0)Homo sapiens (human)
membraneNeutral amino acid transporter B(0)Homo sapiens (human)
melanosomeNeutral amino acid transporter B(0)Homo sapiens (human)
extracellular exosomeNeutral amino acid transporter B(0)Homo sapiens (human)
plasma membraneNeutral amino acid transporter B(0)Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (53)

Assay IDTitleYearJournalArticle
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID26797Partition coefficient (logP)1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Quantitative structure-activity relationships of the bitter thresholds of amino acids, peptides, and their derivatives.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1397319Activation of human CA1 by stopped-flow CO2 hydration assay
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID233320Bitter threshold value; NB denotes 'Not bitter'1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Quantitative structure-activity relationships of the bitter thresholds of amino acids, peptides, and their derivatives.
AID681113TP_TRANSPORTER: inhibition of L-tryptophan uptake in Xenopus laevis oocytes2001The Journal of biological chemistry, May-18, Volume: 276, Issue:20
Expression cloning of a Na+-independent aromatic amino acid transporter with structural similarity to H+/monocarboxylate transporters.
AID1397320Activation of human CA2 by stopped-flow CO2 hydration assay
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1397322Activation of Trypanosoma cruzi CA preincubated for 15 mins followed by CO2 addition by stopped-flow assay
AID58929Ischemic myocardial residue fraction of [13N]-labeled amino acid was observed with a single pass uptake technique in open-chest instrumented dogs (control - 17.3+/-6.1)1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
13N-labeled L-amino acids for in vivo assessment of local myocardial metabolism.
AID1397321Activation of Leishmania donovani chagasi CA preincubated for 15 mins followed by CO2 addition by stopped-flow assay
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID22735Ischemic myocardial half-life measured after intracoronary injection of [13N]-labeled amino acid in dogs (control - 15.9+/-0.2)1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
13N-labeled L-amino acids for in vivo assessment of local myocardial metabolism.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1811Experimentally measured binding affinity data derived from PDB1998Journal of molecular biology, Apr-24, Volume: 278, Issue:1
The structure of glutamine-binding protein complexed with glutamine at 1.94 A resolution: comparisons with other amino acid binding proteins.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB1998Journal of molecular biology, Apr-24, Volume: 278, Issue:1
The structure of glutamine-binding protein complexed with glutamine at 1.94 A resolution: comparisons with other amino acid binding proteins.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18,077)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905164 (28.57)18.7374
1990's3254 (18.00)18.2507
2000's3922 (21.70)29.6817
2010's4020 (22.24)24.3611
2020's1717 (9.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials787 (4.13%)5.53%
Reviews1,633 (8.57%)6.00%
Case Studies283 (1.48%)4.05%
Observational25 (0.13%)0.25%
Other16,334 (85.69%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]